



Tenovus Cancer Care

Annual Report & Accounts

For the year ended 31st March 2018

Registered Company No. 00943501

Registered Charity No. 1054015

TUESDAY



A7XNKDT4

A28

22/01/2019

#22

COMPANIES HOUSE

Report of the Trustees for the year ending 31 March 2018

Chair's Report

2017/18 was another successful year for Tenovus Cancer Care and we supported 7,827 cancer patients and their loved ones across the UK. We've developed and extended our services so we can reach more people and nearly 50% of our clients (3,714) were new referrals.

Our Support Line continues to be the only service of its kind in Wales, and this year our nurses handled over 11,000 calls with people worried about cancer. As well as a chance to speak directly to a specialist nurse, it's free and open 365 days a year.

We also continued to provide our Cancer Callback service and made regular support calls to nearly 800 cancer patients during their treatment. That's 22% more than last year, meaning more people were able to have their questions and concerns addressed by one of our nurses.

We know that after pain, money worries are the biggest concern for cancer patients. Navigating the complex welfare system can be overwhelming, especially if someone's feeling unwell, tired or unable to concentrate. This year our Cancer Support Advisors helped people affected by cancer access £4million worth of benefits and grants (equating to £6.5million annually), and handled 5,490 applications, an increase of 51% on last year. We were also able to access over £600,000 for clients through our Money Advice service, either by money gained or debts written off.

Singing continues to be a huge part of how we support cancer patients and their loved ones, and this year 2,121 people came to one of our Sing with Us rehearsals. Our choirs across Wales and England bring people together who might feel isolated and lonely, every single week.

For over nine years our Mobile Support Units have brought treatment closer to home. This year we delivered 5,400 chemotherapy and other treatments, saving cancer patients time, money and stress. I'm excited to say we're expanding this service, and this year we began building our third Unit which will be the world's largest mobile chemotherapy space. This new service will hugely increase the amount of chemotherapy patients we can see, so more patients have more precious time with the people they love.

This year we developed a new service which focuses on offering support for people who might be struggling with negative thoughts, and are having difficulty living with and beyond cancer. Our ACTivate Your Life courses are based on Acceptance and Commitment Therapy and will let us reach more people struggling with the emotional effects of cancer. We look forward to rolling them out in 2018/19.

In 2017/18 we continued to fund life-saving and life-changing cancer research, including the next stage of our More than Singing choir research. We had 50 active grants running, amounting to funding of over £2million. This year we issued a call for our iGrant applications and received 35 Expressions of Interest. Following review by our Research Advisory Group and a panel of experts, six projects have been recommended for funding next year.

But we were only able to do all this thanks to the support and enthusiasm of our wonderful volunteers. They are the absolute driving force of our organisation and this year gave over 300,000 hours of their time. As well as our volunteers we must also recognise the fantastic generosity and commitment of all our donors and supporters, our Patrons, staff and Trustees.

After being Chair of this wonderful organisation for six years, and a Trustee for a total of eight, the time has come for me to step down. I'm pleased to be handing the role to Professor Malcolm Mason OBE. Widely regarded as the most distinguished cancer doctor in Wales, we are extremely lucky to have him as our new Chair. I have every confidence he will continue to lead the charity forward in the years to come, so that Tenovus Cancer Care will always be there to support cancer patients and their loved ones, when they need it.

Thank you.

Richard Sims
Chair of the Board of Trustees

Trustees' Report

In this document, we set out the report and accounts of Tenovus Cancer Care for the year 1st April 2017 to 31st March 2018.

As the Board of Trustees we do this under the Companies Act 2006, the Charities Act 2011, and the Statement of Recommended Practice: Accounting by Charities effective January 2015, and applicable accounting standards.

Objectives and Principal Activities of Tenovus Cancer Care

Tenovus Cancer Care works towards a long term vision: a future where fewer people get cancer and one where everyone will have equal access to excellent treatment and support.

We have referred to the guidance contained in the Charity Commission's "general guidance on public benefit" when reviewing our aims and objectives and in planning our future activities. In particular, the Trustees have considered how planned activities will contribute to the aims and objectives they have set.

Our core Mission is to bring practical advice, emotional support and treatment to where it matters most; the heart of the community. We help people with cancer and their loved ones cope, and through our vital research, we offer hope.

What we do:

Our specialist Cancer Support Team (CST) provides both practical and emotional support to cancer patients and their families.

Our Mobile Support Units and free Support Line ensure we can reach cancer patients and their families closer to home.

We fund an outstanding and dynamic programme of cancer research to find improved treatments and preventions.

We raise awareness of the issues faced by cancer patients today.

The strategic aims for the charity are:

- To provide support and treatment to people with cancer and their loved ones, closer to home in unique ways
- To represent the needs of people with cancer and their loved ones
- To conduct and fund research to improve cancer outcomes and experiences
- To work with communities to develop healthy lifestyle programmes

Achievements & Performance

Cancer Support Services

Tenovus Cancer Care wants to make sure that everyone has access to the best cancer care and support, wherever they live. That's why we provide treatment and support in communities across the country, working closely with the NHS and our partners to make sure we don't duplicate our services, and that every pound raised counts.

With around 19,000 people in Wales diagnosed with cancer each year, and that number on the rise, our cancer support services are understandably at the heart of what we do.

Our dedicated Cancer Support Team (CST) helps people affected by cancer with a range of free services for as long as they are needed. We complement the clinical care that people receive from the NHS by supporting them at diagnosis, through treatment and beyond.

We differ from many other cancer charities as our focus is helping anyone affected by cancer. A cancer diagnosis affects the entire family; that's why we support not just the patient, but also their family and friends. That way we are able to help as many people as possible.

What we achieved in 2017/18

Whilst we are still seeing the numbers of people diagnosed with cancer each year increasing, we are also seeing an improvement in survival rates. This means there are more and more people living with, and beyond cancer, and the impact and effect of this can last for years. That's why our services are so important. We're there at every stage of the cancer journey and last year we supported 7,827 people, of which nearly half (3,714) were new referrals.

We're committed to continually developing and improving our services so they best meet the needs of people affected by cancer. That's why we're committed to continually evaluating and reviewing our services and activities regularly. In addition to making sure that all of our services and research fit with our strategic aims, and meet people's needs, we want to ensure that every precious penny is spent to best-effect and in-line with our supporters' expectations.

This year:

○ Our nurse-led Support Line handled over 11,000 calls from people affected by cancer

We've been able to help so many people this year because we're the only cancer charity in Wales operating a Support Line from 8am to 8pm, 365 days a year. The service is completely free and confidential, meaning people affected by cancer can get the information, advice and support they need, when they need it. The fact that our Support Line has experienced nurses as part of the team, means we are also able to answer clinical questions and concerns.

Our unique Cancer Callback service has continued to go from strength to strength, giving cancer patients their very own dedicated Support Line nurse who will call them at times that suit them, including evenings, weekends and bank holidays, making it a truly patient-centred service.

We are proud to have continued delivering our Cancer Callback service in four Health Board areas and this year called 787 patients (up 22% on the previous year), each of whom had an average of six calls during the course of their treatment. This service is supporting many cancer patients who do not have a Clinical Nurse Specialist or may not know who their NHS Key Worker is. Our Callback service continues to fill a vital gap in cancer support, answering patient questions, taking the time to listen, and addressing their concerns. As patient demand on the NHS cancer services continues to rise, we aim to expand this service so that we can support more patients and more Health Boards.

Jean Phillips

Five years after his initial prostate cancer diagnosis, Jean's beloved husband Huw sadly passed away. The couple used our Support Line for answers to their questions and concerns throughout Huw's treatment. It meant an awful lot to Huw to be able to speak to one of our nurses in Welsh.

"Being able to speak to his nurse in Welsh meant the world to Huw. He was able to ask her absolutely anything no matter how trivial it may have seemed, and the very serious questions too. Diane would never rush the trivial questions or dwell on the serious issues and the two of them laughed a lot!"

"She was a font of knowledge and also supported me in my lonely role as his sole carer – we had never thought of attendance allowance or a blue badge but Tenovus Cancer Care did, and sorted it out for us."

○ We helped people affected by cancer access £4million worth of benefits (equating to £6.5million annually). In addition, and thanks to 12 months of funding by the Money Advice Service, last year we employed a Debt Advisor who, through money gained or money written off, recovered over £600,000 for our clients. It has been so successful we have already committed to fund a Debt Advisor ourselves next year.

There are many hidden costs of cancer and research shows that next to pain, worries about money matters are the next most significant concern for cancer patients. Patients may have to reduce their work hours or stop working altogether. Occupational sick pay, and how long it is offered for, varies substantially from employer to employer. And

some people may only ever receive statutory sick pay. The financial burden of a cancer diagnosis can be immense on the individual and their family. In addition to this loss in income, they may have additional costs, including travel costs to and from a hospital or an increase in household bills, such as the cost of energy to heat their homes.

Navigating the welfare system is complex for many people, even when they are in good health. This, coupled with welfare reform changes and complex benefits forms that take time and knowledge to complete, can be understandably overwhelming for cancer patients who may be feeling unwell, tired or unable to concentrate. This is where our team of Cancer Support Advisors (CSAs) come in.

Our dedicated team of CSAs understand the importance of giving our patients and their carers the very best advice, providing an outreach service across Wales in both hospitals and communities. They help cancer patients and their families access information, whether they are receiving treatment or follow-up care. We helped people maximise their income and access financial support in the form of grants and benefits in 32 different outreach venues or over the phone. This is vitally important in helping us support patients, no matter where they live.

This year:

- Our advisors completed 3,097 assessments of which 156 were through our new Debt Advice Service
- The total number of applications submitted for the year was 5,490; a 51% increase on the previous year
- While the benefits and grants we have secured have given patients financial security, we continue to help service users to obtain blue badges to give them independence and freedom and a better quality of life, at a difficult time
- We helped 65 people challenge unfavourable benefits decisions, made 31 appeals, and even prevented six people being evicted and made homeless
- In addition we've helped suspend a number of bailiff's warrants by arranging alternative deductions or payment plans. This has saved our already vulnerable clients, the distress of having their possessions seized
- We successfully retained the Advice Quality Standard and continue to be the only cancer charity in Wales to hold this accreditation. We are extremely proud of this standard as it confirms that our staff are trained to the very highest level, and are best-placed to meet the needs of cancer patients and their families.

Martin Jennings

Martin started treatment for myeloma in 2017 and has been struggling with mental health issues for most of his adult life. After being turned down for Personal Independence Payment (PIP) he got into debt and turned to Tenovus Cancer Care for help with managing his finances.

"On one visit to hospital I met with a Tenovus Cancer Care advisor called Michelle. She helped me deal with my debt and cleared it, including loans, credit cards and overdrafts; filling out all the paperwork necessary. I wouldn't have had any idea what to do myself, and she sorted it all."

"Michelle even found that I had a hospital plan insurance policy that I hadn't thought to bother with. I'd been in hospital for eight weeks so she managed to make a claim on my behalf. My treatment has been a bit of a test but overall my mental health has improved through receiving the help from Tenovus Cancer Care."

○ We have seen over 1,700 people each week benefit from singing in one of our 19 Sing with Us choirs

Singing continues to be a very big part in how we help our patients and their loved ones cope with a diagnosis of cancer. Our choirs stop people feeling isolated and lonely, and research shows that singing and being part of our choirs makes an enormous difference; it lifts spirits and it can even help reduce pain and the side effects of treatment. We continue to support as many people as we can under our framework of making our choirs fun, fulfilling and supportive.

This year saw the culmination of the data collection for the research conducted with the Royal Marsden Hospital in our Sing with Us London and Sutton choirs. With all data collected, the analysis phase has started in earnest and we look forward to receiving the full research report and findings later in 2018.

With the research and funding for London and Sutton ending during the year, we had to review our current financial situation and the benefits of continuing these choirs. While we were able to secure the short to medium future of these two Sing with Us choirs, we had to make the difficult decision to close our first ever choir, in Guildford. Sing with

Us Guildford had initially been set up with three years' worth of private funding which came to an end during the year. Following a review and a number of attempts to find additional funding, the choir closed in March, which means that at the end of the year we are supporting people affected by cancer in 18 Sing with Us choirs.

Throughout 2017/18 we have spent time continuously reviewing our choirs to ensure we are delivering the best service possible at the highest standard, with plans in place to develop this further in the next year.

This year:

- Our Cwmbran, Carmarthen, Abergavenny and Bridgend choirs all celebrated their 5th anniversary
- We supported 1,731 cancer patients and people affected by cancer regularly through the year, while a total of 2,121 have attended a rehearsal during the year. This is our highest recorded membership to date
- The number of choir members who have or have had a cancer diagnosis has increased on the previous year
- Throughout the year, the Sing with Us choirs performed at 320 gigs or events, continuing to raise awareness and donations
- We were invited to two international staff conferences during the year by two major pharmaceutical companies – Gilead (Lisbon) and Ipsen (Vienna). We took a total of 60 choristers to these conferences from our Aberystwyth and Cardiff North choirs, and were given an incredible combined donation total of £13,000!

Sybil Fowler

After overcoming breast cancer herself in 2011, Sybil's husband Rob was diagnosed with pancreatic cancer in 2013. The cancer was picked up quite late and the couple were told that Rob only had two months to live. During that time Sybil found support through our Cardiff North Sing with Us choir.

"Tenovus Cancer Care's support helped me more than anyone will ever know. The Sing with Us choir were incredible. They sent me messages and even sang at Rob's funeral which was amazing."

"I didn't feel alone because there was someone there for me all the time. They were there for me at my darkest moments. If you've never been part of anything like this, you should try it. You can go to choir on a miserable rainy night, feeling low, but by the time you come out, you feel uplifted. It's the best therapy you could ever have."

- **Our Mobile Support Units brought treatment closer to home, giving cancer patients more time with the people they love.**

This service saves people time, stress and the extra costs of travelling to the hospital. For the past nine years, it has helped move patients away from hospital locations which are becoming increasingly congested, whilst acting as a gateway to all of our other support services.

For cancer patients, fewer miles travelled means more time doing the things they enjoy including spending time with the people they love.

This year:

- Working in partnership with the NHS we've helped deliver 5,400 chemotherapy and other treatments closer to home, in communities across the country
- Our two units travelled more than 19,000 miles
- We welcomed more than 7,800 visitors on board
- We have begun exercise classes on board one of our units as part of a pilot with ABMU Health Board. The pilot is looking at the benefits of exercise for lung cancer surgery patients as part of their pre-habilitation and rehabilitation. Early results show that some patients who were ineligible for surgery, have responded so well to the exercise intervention that they have either moved themselves to be ready for, or have undergone surgery. With the right support, some patients have even moved from palliative to curative care
- We have started the build of a new Mobile Support Unit that will have the capacity for seven chairs; the current unit has space for four. It will be the world's largest mobile chemotherapy unit and will allow space for patients' loved ones to sit with them. We are very excited to see how this extra capacity helps us to support more patients and Health Boards. It will launch towards the end of 2018

Claire Daniels

Claire from Port Talbot found it much easier to visit our Mobile Support Unit on a Saturday for her treatment. She's part of a local breast cancer support group and enjoys seeing the regular friendly faces on the Unit.

"I normally work Monday to Friday, so when the doctor told me I could have my treatment on Tenovus Cancer Care's Mobile Support Unit on Saturday – I jumped at the chance. The location of the Unit means I don't have to go into Swansea on a busy Saturday. I can do a bit of shopping afterwards too!"

"It's the same nurses from the hospital that you see on the Unit, so you feel reassured – but it's the convenience of it that's the best thing. You're in and out and there's no hanging about. When you have treatment in the hospital, you're always worried that you're going to catch a cold or get ill, but you don't get that on the Mobile Support Unit. That gives you peace of mind."

○ Our counsellors listened for 1,417 hours

Our counsellors offered emotional support so that no-one had to cope with cancer alone. The service was available to help those with a diagnosis to cope, to help people to adapt to living with a cancer diagnosis in their family, and to reduce stress, anxiety and depression.

Unfortunately, due to the financial constraints, we had to take the difficult decision to close our counselling services. The nature and cost of counselling meant that we were not able to reach and support as many people as we would have liked.

Since the closure of our counselling service, we have launched ACTivate Your Life – Affected by Cancer. This new service allows us to achieve a far greater reach and impact with patients and their loved ones, who are living with and beyond a cancer diagnosis. In some cases, we will be able to prevent individuals from ever needing to access one-to-one counselling.

While we understand this will have impacted a number of people, we believe this was the right decision to allow us to continue to support people affected by cancer, using the funding available, as responsibly as we can.

This year:

- 313 individuals were offered counselling sessions
- 69.7% of counselling clients were cancer patients
- We honoured the remaining sessions of any existing clients and ensured everyone on our waiting list received the support they needed

Wayne John

Wayne was diagnosed and received treatment for bowel cancer in 2014. Following an operation his mental health began to deteriorate and he couldn't control his thoughts. He was directed toward ACTivate Your Life and the course helped him so much that Wayne is now a volunteer presenter for our ACTivate Your Life – Affected by Cancer support service.

"ACTivate Your Life taught me how to separate myself from my thoughts and how to manage the way I lived my life. When I started the course, my self-confidence was so low I couldn't even sit in the back row of chairs. I took one of the chairs and put it against the wall at the back of the room. The course helped me so much."

"Presenting the course to a group of people and knowing that you're helping them is as good a therapy for me as it is for them. It has given me my identity back. I would encourage anyone who may be struggling as a result of cancer to join the ACTivate Your Life – Affected by Cancer course."

Aims for 2018/19

- Increase the number of people affected by cancer, helped by our Cancer Support Team
- Through patient engagement, improve our client experience to ensure that every contact counts, and that every person receives a holistic service based upon their needs
- Make it easier for people, including those in hard-to-reach places, to access our services and find information that's relevant and specific to their needs
- Improve people's mental well-being and social engagement through our ACTivate Your Life programme or Sing with Us choirs
- Extend the reach and use of our Mobile Support Units by building on existing and forging new relationships with NHS partners
- Provide opportunities for people to improve their own physical activity, diet and nutrition

A future without cancer

The Tenovus Institute for Cancer Research, based at the University Hospital of Wales, was opened by HRH Princess Margaret on the 14th April 1967. Since then, the Institute has made a number of cancer discoveries, from finding that the contraceptive pill was particularly effective at halting the growth of certain breast cancers (Tamoxifen), to playing a key role in the research and clinical trials that led to the drug Zoladex - a common treatment for both breast and prostate cancer patients today. We have found new ways to diagnose cancer, better ways to treat it, while making life easier for people living with cancer.

While we've already done so much to help cancer patients around the world, our work goes on; not just in the lab, but in the community too. In the last 12 months we have monitored the activity of 50 active grant awards. This amounts to £2,179,866 worth of research over the duration of the award.

○ We continued to fund PhD studentship research projects in labs across Wales

We have a proud history of supporting successive generations of cancer researchers, and over the past five decades we have supported over 250 PhD students. These projects address the more fundamental and comprehensive challenges that cancer creates. We currently have PhD studentship research projects in Cardiff, Swansea and Bangor Universities, and fund over £1million of research that will really help to create a world where no one dies of cancer. We are looking forward to putting out a call for new PhD applications later in 2018.

○ We approved funding for further iGrant projects which look to address the needs of cancer patients in the community

Our iGrants scheme selects and funds a number of high-quality research projects that make a real difference to people affected by cancer today. The scheme identifies research projects that provide practical solutions to the issues faced by cancer patients and their families.

This year our Research Advisory Group (RAG), which includes people who have experience of cancer, received 35 'Expressions of Interest'. These were reviewed by the group and a panel of experts, who recommended six new projects for funding, which will start on 1st April 2018. With a total investment of over £186,796 we are looking forward to seeing the practical benefits this research will bring cancer patients in the future.

○ We approved funding for five KESS projects

The Knowledge Economy Skills Scholarships (KESS) is a major European Convergence programme led by Bangor University on behalf of the Welsh higher education sector. KESS offers collaborative research projects (Research Masters and PhD) linked with a local company partner. As a KESS company partner, Tenovus Cancer Care has again partnered on five KESS studentships, taking our total number of active KESS studentships to ten. In doing this we have prioritised projects which will help us meet our charitable aims.

○ **We developed partnerships to share and learn best practice in research, while avoiding duplication of effort**

As one of Wales' largest cancer research funders we are able to work with other organisations to make sure the very best cancer research projects are supported. Working in partnership helps to make sure money, time and resources are best used.

This year we worked in partnership to promote our research to key stakeholders, patients and the public through the National Cancer Research Institute's (NCRI) Patient Public Involvement Steering Group. Other close working includes playing a significant role in the promotion and encouragement of participation of a large scale survey, working with the NCRI and James Lind Alliance, to gather the priorities of individuals living with and beyond cancer. As a result, over 10% of responses to this UK survey came from Wales which is double the Welsh proportion of UK residents affected by cancer, meaning a very strong representation of Welsh views. We also remain an active member of the Association of Medical Research Charities (AMRC) which helps us to ensure our processes and research outputs maintain the highest standards.

○ **We raised awareness of our work by communicating our research successes far and wide**

To raise awareness of our work and highlight the difference we make to people affected by cancer, it's important for us to communicate our research activity as widely as possible, particularly to our supporters and the research community.

Our Research Engagement Officer helps to raise the profile of our research amongst our supporters, academics and the general public including schools. Successful engagement events included interactive stalls at Greenman Festival and at Techniquet Glyndwr. Over these two events, we spoke to 900 people making use of interactive activities to promote cancer research and education. Tenovus Cancer Care also played a central role in organising a 'Tackling Cancer Together' event, bringing together 23 organisations to raise awareness of cancer, research and available services.

To help promote the vital research we fund, we maintained a Tenovus Cancer Care research presence at various conferences, such as the Wales Cancer Conference and NCRI conference, to highlight our research and to promote funding opportunities we had available. In addition to promoting our research online and to the public through the media and other engagement activities, we supported our PhD students to attend national and international conferences, so they too can raise awareness of our research and the wider charity. Over 50 engagement activities were reported by our funded researchers over the last 12 months including giving presentations, holding events or being awarded prizes for their work. Countries where we have had international reach through conference presentations included Switzerland, Iceland, Spain, Cyprus and Germany.

○ **We continued to focus on the reporting and evaluation of our research, to assess its impact and make sure it best meets the needs of cancer patients**

It's so important that we use the money we receive to fund excellent research that meets the needs of cancer patients and their loved ones.

To achieve this, we require all our grant holders to sign terms and conditions so that we can make sure projects proceed as planned. We also use specialist online reporting tools to collect information, which is then reviewed by one of our independent scientific committees and our Research and Patient Services Committee, allowing us to accurately assess the impact of the research we fund.

This year we oversaw a review and overhaul of some of our procedures, practices and reporting methods in order to ensure our systems are as robust, transparent and equitable as possible. This has improved the quality and relevance of applications, and also allowed for better reporting of outputs. This in turn has enabled us to disseminate the impact of our research, which helps us promote and encourage further applications, partnership working and opportunities.

○ **We made sure Tenovus Cancer Care's services really help our clients**

It's important that Tenovus Cancer Care services are robustly evaluated to make sure they meet the needs of the clients who use them. As we offer a range of support services, we use a varied set of evaluation tools and methods to

scrutinise them, and make sure our support is the very best it can be. We sample patients, family members and professionals so that we evaluate based on feedback from all the groups that might potentially access our services.

In the last 12 months, we have again surveyed many of our own services to measure satisfaction and areas for improvement, which will help guide our services in 2018/19.

o **Our Sing with Us choir research**

At the start of 2016/17 we published our More than Singing choir research. This research study with the Royal College of Music in London looked to see if singing in a Sing with Us choir had measurable biological effects. We took saliva samples from 194 choir members, before and after a rehearsal. After just one hour of singing we could measure a reduction in the stress hormone cortisol and changes in a range of biological markers of immunity and inflammation. These exciting results have now been published in a peer reviewed journal and received large interest and worldwide media coverage. All our research to date complements what we have previously found, and shows that singing in a choir is not just a fun activity for people affected by cancer; it can provide real support and has significant benefits.

Following the success of the More than Singing research, a new two year research project was launched between the Charity and the Royal Marsden Hospital. The aim of this research was to take a more in-depth approach to the More than Singing research, studying specific groups of people affected by cancer and measuring the benefits to these groups.

We're now in the second year of this project, which continues to progress well with over 160 participants enrolling through the Chelsea and Sutton Sing with Us choirs. All the data is being analysed and we look forward to sharing the results next year.

Aims for 2018/19

- o Launch our new Research Strategy Grants to help us develop our services and activity provision, and use our resources more effectively
- o Put out a PhD call to fund research which focusses on all types of cancer and at all stages of the patient pathway
- o Help strengthen and grow the research community in Wales by supporting knowledge sharing, and expert mentoring and people development, helping to build future ambassadors of Tenovus Cancer Care
- o Continue with our KESS and iGrant schemes, selecting and funding a number of high quality research projects that can be translated into public and patient benefit
- o Grow our sponsorship opportunities to generate income to fund research, in addition to further developing partnerships in funding and promoting research
- o Continue with our engagement strategy to raise awareness of our research and the impact it makes and to encourage the youth market to get involved during their future careers

Prevention is better than the cure

At Tenovus Cancer Care we are passionate about developing realistic cancer prevention and healthy lifestyle programmes.

Research shows that around 40% of all diagnosed cancers in the UK could be prevented by simple changes to lifestyle; Wales has one of the highest incidences of cancer and some of the poorest survival rates in Europe.

Unfortunately, poor lifestyle behaviours such as smoking, bad diet and lack of exercise, excessive alcohol consumption and UV exposure are highly prevalent across Wales, resulting in a poorer population health profile. This is why we work so hard in communities across the country to help people to reduce their risk of cancer.

By targeting preventable cancers, our programmes have empowered individuals to change their behaviours and help reduce their risk of cancer.

This year:

○ **We ran health promotion campaigns aimed at helping the greatest number of people possible**

○ **Here Comes The Sun**

Skin cancer is the most common cancer in the UK. Our sun awareness campaign Here Comes the Sun focuses on sharing information on the importance of good practice including the correct use of sun cream, raising awareness of appropriate application, and other 'best practice' advice.

Each year the campaign is supported by our Sun Cream Van (a converted ice cream van) and a team of dedicated Sun Safety Advisors who, armed with sun cream samples, give out advice and information at schools, on beaches, and at community and national events.

This year we had 1,800 sun safety conversations over the course of the campaign. Through telephone call-backs, we followed up a sample of participants to determine whether our campaign made a difference. From these call-backs, nearly 84.7% reported they had made a positive behaviour change. This is a 17.4% increase compared to last year, which is very positive.

These intervention conversations are really important as these people now have a greater awareness of the importance of lifestyle on minimising the risk of developing skin cancer and additionally, are more aware of the symptoms which will help with early diagnosis.

○ **Quit with Us**

We continued to run and develop our Quit with Us campaign to help people quit smoking. Smoking is still the biggest cause of preventable ill health in Wales with 19% of the Welsh population still smoking.

Following the success of the previous year, we continued to work with a number of community pharmacies in South Wales to help us distribute free sample packs of Nicotine Replacement Therapy (NRT) to smokers interested in quitting. During this campaign, we held 273 brief interventions for smoking cessation with 86.1% indicating that they wished to attempt to quit smoking. Follow-up calls were made to a sample of those participants, of which 69.4% had made a total or partial attempt as a result of the campaign.

This year, for the first time, we explored using other social media opportunities as a way to reach and support more people. This led to our first ever 'Facebook Live' question and answer session, which was well received. We also set up a Facebook group to connect people who are trying to quit, share stories, advice and tips, and to positively re-enforce their efforts to quit.

○ **We explored how we can reach a younger generation, in line with our ambition to prevent cancer earlier and develop our schools resource programme**

This year we attended 28 schools and colleges in South and West Wales in our Sun Cream Van to deliver our Here Comes the Sun campaign to a younger audience. The campaign was adapted to make it more accessible and interactive for children, with the aim of it being more fun and in-keeping with the age of the audience.

This was incredibly well-received by the schools involved and we will look to expand on this next year, while also developing other areas of prevention where we can explore and raise awareness of other issues relating to cancer.

● **Our Health Check increased awareness of common cancer symptoms and risk factors**

The Tenovus Cancer Care Health Check provides personalised, action-orientated information, and encourages people to adopt healthy behaviours. This includes spotting early signs and symptoms of cancer, taking up screening, and encouraging earlier presentation of symptoms with GPs. It sits alongside our health promotion programmes and forms a part of our integrated approach to positively impacting people's health and well-being.

In 2017/18, we began phase three of the Health Check, in partnership with Cardiff University, and with funding provided by Cancer Research UK and Yorkshire Cancer Research. The purpose of phase three is to robustly test the effectiveness of the Health Check using a random control trial model. We know already, from the previous phase of

evaluation, that our Health Check is an acceptable method of increasing knowledge and awareness in particular with vaguer symptoms, such as weight loss, as a possible indicator of cancer.

During the coming year, and as phase three continues, we will be looking to adapt our Health Check using the feedback from phase two, making it as good as it can be to support people affected by cancer.

○ **We raised public awareness of the growing link between obesity and cancer**

The links between cancer and obesity are well documented and it is estimated that more than one in 20 cancers are linked to people being overweight or obese. 59% of adults in Wales are classified as overweight or obese.

In response to this challenge we piloted a weight management project in Glynneath with funding from the Maesgwynn and Sellar Community Benefit Funds. The project called 'Foodwise for Life' is an eight week structured programme which utilises evidence-based approaches to weight management. The programme was designed and evaluated by Nutrition Skills for Life (ABMU Health Board), and was delivered in Glynneath by trained Foodwise community facilitators supported by our staff.

We are now in the process of training more staff to deliver more courses across Wales, where we hope to be able to provide an accessible service to people in hard-to-reach areas. The aim of the course is not only to lose weight in those eight weeks, but provide participants with the skills to continue to lose weight and allow them to make permanent, long term changes to their diet.

○ **We worked with partner organisations to promote positive health behaviours with hard-to-reach or high-risk groups**

At Tenovus Cancer Care we aim to not duplicate existing activity. Wherever possible, we aim to construct partnerships to deliver effective messages or interventions into the heart of communities.

This year we are proud to have worked with a large number of partner organisations in communities across the country, including Public Health Wales, Communities First, local Health Boards, local councils, GP surgeries, Community Pharmacy Wales, schools, colleges and workplaces. Working in partnership enables us to reach out to as many people as possible, who we may otherwise not be able to reach and support.

Aims for 2018/19

- Raise cancer awareness amongst younger people through a schools programme, encouraging healthy lifestyles and helping them to spot symptoms earlier
- Using our Tenovus Cancer Care Health Check, work with the adult population to promote healthy living, cancer prevention and early detection
- Partner with organisations to promote positive health behaviours with hard-to-reach or high-risk groups

Raising money so we can support more people and fund vital cancer research

This year we again faced challenges due to external factors beyond our control. Negative media coverage of charities persists and we continue to be asked more questions by funders and the public.

Despite this, our total like-for-like income was up compared to the previous year by £622,706, thanks to the continued generosity of our donors, and the hard work and efforts of our valued volunteers and staff.

As a result of a full review of our income generation activities, carried out during the first quarter of the year, we achieved our goal of becoming more efficient. We were able to reduce our total costs by £348,482 and the net contribution to the charity, excluding a £1million donation from the Moondance Foundation for a fourth Mobile Support Unit and excluding legacies, increased by £617,705.

This year:

- **Our 'Closer to Home' Capital Appeal to raise £1million to fund a new Mobile Support Unit was a huge success**

Thanks to the hard work and dedication of the Closer to Home Capital Appeal Committee, a group of ten volunteer business people, we exceeded our £1million target to fund the build and initial running costs of a third Mobile Support Unit. This was achieved with substantial pledges from the Walk the Walk Foundation, Welsh Government, the Fairwood Trust, the Simon Gibson Charitable Trust and CARTEN100. There were also many smaller, generous contributions from a large number of businesses and individuals.

Thanks to the Closer to Home Appeal Committee, we also secured a further £1million in funding for a fourth Mobile Support Unit from the Moondance Foundation. This is an incredible achievement and we are indebted to the Moondance Foundation for their incredible support, as well as to our Appeal Chair, Brian Lakin of Sigma 3 Kitchens, and his Appeal Committee for their hard work and dedication on our behalf.

These new Mobile Support Units will be the largest mobile chemotherapy units in the world and will allow us to treat many more patients. Our third Unit is scheduled for delivery in the summer of 2018 with the fourth due in the spring of 2019.

- **We continued to increase the number of weekly lines in our lottery, and improve profitability by partnering with a new lottery provider**

During the year we partnered with Make a Smile (a not for profit lottery operator owned by St. Helena Hospice) which increased our return on each £1 played from 50p to 75p. Whilst net profitability increased, we struggled to find suitable means to recruit new players and we will be addressing this in the coming year.

- **We further grew and developed our activities in the community, including our Friends of Tenovus Cancer Care groups**

The new "Light up the Night" fundraising campaign was really well received, generating over £17,000 in income and is something we will be seeking to build upon in the coming year. During the year we also established two new Friends of Tenovus Cancer groups in England (Southampton and London); along with a further two groups in Wales, bringing the total number of Friends of Tenovus Cancer Care groups to 32. Working with these fantastic groups will continue to be a priority area for our Community Fundraising Team in future years.

- **We increased the net profitability of our retail operations**

This year we saw staff and our valued volunteers work hard to generate increased sales of donated goods in a challenging charity retail sector environment. We saw an increase in income of 2% (£105,835) compared to the previous year. Due to upward movement in the rag market, income from this source was up by 29% (£44,671) compared to the previous year. However, we continued to see depressed sales of new goods due to us needing to clear old stock.

Expenditure was very well controlled this year. Total expenditure, including central overheads was down by £208,284 compared to the previous year, leading to an increase in net profit of 17% compared to 14% in 2016/17.

- **We restructured our Income Generation Department to reduce costs, whilst increasing income to provide an enhanced return**

Total income generation costs, compared to the previous year, were reduced by 6% (£348,482) which resulted in the net contribution increasing by 43% (£617,705), plus a further £1million for our fourth Mobile Support Unit.

Aims for 2018/19

- Maximise income generation opportunities from our 75th Anniversary year, including a gala Birthday Dinner
- See our Fundraising and Retail Teams working closer together to grow income particularly through the expansion of our lottery and large scale raffle
- Cost effectively develop our fundraising activities in Powys and England
- Identify and develop new corporate relationships across Wales and England
- Work with our retail staff and volunteers to maximise the profitability of each shop
- Roll out IT to all stores and significantly increase those engaged in online selling of donated stock
- Identify new locations and make a business case for the opening of new shops

Raising awareness of what we do

Our Marketing and Communications Team's priority is sharing who we are, what we do, and the difference we make, as widely as possible. We want people to find out about our services, raise the profile of our research and health and well-being campaigns, encourage more people to get involved, and ultimately raise more funds.

This year we've worked hard on a wide range of projects, supporting teams across the charity. We've launched new services and fundraising campaigns, and reinvigorated our annual communications and activities. We've created authentic and engaging content focussing on community, to help strengthen our brand and connect more deeply with our audiences.

This year:

- **We continued to embed the refreshed Tenovus Cancer Care brand, including through our 75th anniversary plans and the community activities, making sure the charity was portrayed in a clear, consistent and on-brand way with the aim of increasing unprompted awareness of the charity**

In 2017/18 we've continued to embed our brand across all our channels, and our 75th anniversary has been a fantastic opportunity to help enhance their reach. We've created specific fundraising campaigns like our 75th Birthday raffle and 'Pass the pledge' to engage with corporates, and are building our birthday into our volunteering ask. We've created a section of the website to look back at our achievements, as well as looking ahead to our special anniversary year.

As well as this, our annual Free Wills Month helped bring our brand to millions of homes through TV advertising. This was an excellent opportunity to highlight our 75th anniversary and our heritage, in a campaign which showcased our history of funding life-saving research.

For our Closer to Home Appeal, fundraising for a third Mobile Support Unit, we needed to adapt our brand to specifically appeal to an audience of major donors, organisations both large and small, as well as members of the public. Key to this campaign has been sharing the stories of people who've benefitted from the Unit, strong key messages and engaging design.

In July we received the results of the Celtic Charity Awareness Monitor, a piece of independent market research which gave our unprompted awareness at 4%*. Whilst we saw a drop from the year before, this trend was reflected in all but one of the comparator charities featured in the survey. In addition, the charity's activity during the 2017 survey period was substantially less than in 2016 when our Free Wills Month, new shop fronts, and the launch of our More than Singing choir research (which generated international media coverage), all helped to generate awareness of Tenovus Cancer Care. With all the activities and events we have in plan for our 75th we would hope to see an increase in awareness when this survey is next run.

Like most organisations, we're anticipating being substantially affected by the new General Data Protection Regulations (GDPR) which come into effect early 2018/19. This year we've worked hard in preparation for this, specifically around our marketing consent. We created a dedicated consent campaign and developed a range of communications to our stakeholders reiterating the importance of their support. As well as cleansing and refreshing our database so we can continue to contact our supporters going forward, we used this as an opportunity to reconnect with our stakeholders, and strengthen our brand by highlighting our transparency and responsibility.

* Celtic Charity Awareness Monitor, May-Jun 2017, nfpSynergy | Base: 1,000 adults 16+, Wales

- **We supported the rest of the organisation and help them achieve their objectives, while making sure the charity's work is presented in a balanced way**

This year the Marketing and Communications Team has continued to work with teams across the organisation to help deliver their objectives. Given the breadth of our work and activities, making sure the charity is presented in a balanced way is always challenging. But we've worked hard to make sure both our resource and opportunities for exposure best represent the charity as a whole.

We've played a key part in supporting the launch of the new ACTivate your Life service, as well as the activity around the expansion of our Mobile Support Unit service. We also supported a new year-round fundraising campaign (Light up the Night), the relaunch of the charity's lottery, and our participation in the Big Give; a short-term high-intensity, match-funding campaign which raised over £20,000.

As well as supporting teams across the organisation with expertise and advice, we've provided teams with training around key skills like photography and social media.

- **We continued to develop and use stories in an authentic and engaging way, to show the impact of our work and the difference we make to the lives of cancer patients and their loved ones**

Real stories are one of the most powerful ways to share the impact of our work in the communities we support. This year we've continued to embed storytelling into even more of our activity, developing authentic content.

Our dedicated Storyteller has travelled across England and Wales to collect the stories of our service users, fundraisers, researchers and volunteers. We've shared those stories online, across social media, in the press, at events and in print.

This year we've increased the number of stories shared across our website, and have featured more service users' content as part of a series of blogs. We've adapted these to tie in with campaigns like Breast Cancer Awareness Month or Volunteers Week. We've also set ourselves the challenge of sharing 75 stories over the next year, to celebrate our 75th anniversary and will be working on this into 2018/19.

We've also continued to use stories as a key part of our internal communication strategy. Sharing stories with our volunteers and staff, has helped them better understand the impact their hard work has on people affected by cancer, no matter what their role.

- **We continued to develop and implement internal communications so that staff are aware of the charity's news and activities, and feel valued and part of the organisation**

This year we have expanded our Chat with Us magazine, which goes to choirs, shop staff and volunteers, and our Friends of Tenovus Cancer Care groups. The magazine includes details of our campaigns, services and events, helping to raise awareness and engagement amongst our key stakeholder groups.

Each group gets a tailored version which features relevant cross-departmental content. We produced four issues in 2017/18 and feedback has been extremely positive.

On top of this we've continued to support the wider organisation to improve internal communication by providing good staff inductions, encouraging staff to regularly visit our calendar of activities and communications, and promoting best practice.

Looking ahead to 2018/19 we will undertake a charity-wide Internal Communications Review to ensure we are keeping everyone in the organisations up-to-date with the charity's news and activities, so they feel a valued and vital part of the organisation.

Aims for 2018/19

- Use our resources effectively to support the rest of the organisation and help them achieve their objectives
- Continue to embed the Tenovus Cancer Care brand, throughout our 75th anniversary year, making sure the charity is portrayed in a clear, consistent and on-brand way; with the aim of increasing unprompted awareness of the charity
- Plan, design, build and launch a new, mobile responsive website by the end of 2018/19
- Continue to develop stories and other content to show what we do, the impact of our work and the difference we make to the lives of people affected by cancer
- Develop and manage Tenovus Cancer Care's external communications, while undertaking a review of our internal communications so that staff are aware of the charity's news and key activities

Supporting cancer patients in other ways...pushing for change

In Wales, more than 19,000 people each year will receive a cancer diagnosis. Cancer is now so prevalent, 1 in 2 of us are likely to receive a diagnosis in our lifetime. One of the most startling facts is that 4 in 10 of all cancers are preventable with lifestyle changes.

The story of cancer in Wales and the UK is a mixed one. While politicians in England and Wales sometimes score points on the latest cancer waiting times or access to treatments, survival in the UK as a whole lags behind much of Europe. Survival rates in Wales and the UK show we still haven't been able to get early diagnosis right. It's one of the most pressing issues we face to improve outcomes for people affected by cancer.

Tenovus Cancer Care is passionate about representing the needs of cancer patients and their loved ones - being a voice to champion their cause. We continue to push for major investment in infrastructure and in the diagnostic workforce to effectively catch cancer at the earliest possible stage.

Our in-house Policy Officer is responsible for identifying evidence-based interventions and works with policymakers and planners within the NHS to make sure the best evidence is being put into practice. Linked closely to decision makers, he ensures people affected by cancer have a say in major decisions. Having returned from a sabbatical, our Policy Officer spent the second half of 2017/18 reviewing and updating the charity's policy positions so that they continue to be up-to-date, robust and truly reflect the needs of people affected by cancer. This piece of work will be completed early next year and will put the charity in a strong position to work with the various political parties as they start to develop their manifestos in 2019, in preparation for the elections in 2021.

This year:

- In addition to reviewing our policy positions, we effectively held the Welsh Government to account on their commitments to an £85million New Treatments Fund and reform of Individual Patient Funding Requests (IPFR)
- We continued to be an active member of the Wales Cancer Alliance, a platform to scrutinise the development of Welsh Government policy and shape the future development of cancer delivery plans. We played a full and effective role in shaping the future of the Alliance, helping to redesign their policy positions and repositioning the organisation for the future
- We developed new partnerships with patient groups, and started discussions with another organisation on an awareness campaign that will focus on the importance of early diagnosis, the need for which has been outlined above. The benefits of this work will be seen later in 2018

Aims for 2018/19

- Work with key organisations in Wales, the UK and Europe to represent the needs of cancer patients and their families in Wales

- Take part in Welsh Government and UK Government consultations regarding policies that could impact on people affected by cancer in Wales. Monitor the Welsh Government to ensure that they are delivering on their commitments regarding cancer, health promotion and the support of patients and their families
- Make sure that the public/patient voice is represented in Tenovus Cancer Care's activities

Looking after our people

At Tenovus Cancer Care we're committed to being a great place to work and volunteer. We recognise the direct link between how satisfied and happy our people are, and excellent customer service which in turn means we provide outstanding support to people affected by cancer.

This year we've benefitted from the invaluable support of our volunteers who've generously donated an amazing 300,000 hours of their time. They help us in so many ways including welcoming people to our Mobile Support Units, giving talks in the community, fundraising and working in our network of shops where we couldn't achieve our income without them. Our success relies on our talented and motivated people and we continue to recognise and celebrate the vital contribution they make.

This year:

- **We increased volunteering opportunities across the charity, with particular focus on our Research and Support services and our shops**

Whether our volunteers have a few hours to spare or a few months (or years) we continue to offer a wide range of opportunities and ways for people to support the Charity.

We continued to advertise more volunteer roles than ever before with 526 new volunteers starting with us or supporting us at our events this year. Volunteering with us not only gives people the opportunity to support those affected by cancer and raise money, it also provides ways to learn new skills, develop confidence and meet new people.

We recruited for our new volunteer-led ACTivate Your Life service with 17 people trained so far. They are a mix of patients, students and existing service users who will help us bring this brand new service to people affected by cancer. Their knowledge and experiences have helped us to launch it, and influenced how it can develop over the coming months and years.

Over two thirds of our volunteers help us in our shops and we're committed to providing a wide range of opportunities, where people can develop skills and have fun. Although we haven't increased the actual number of volunteers, we have increased hours given and the responsibilities carried out, which allows us to operate more effectively.

Emma Morris

Emma found purpose in volunteering when she was younger and after volunteering at our Head Office to gain experience, became Assistant Manager of our Rhiwbina Shop.

"Volunteering with Tenovus Cancer Care at their Head Office was a big learning curve. I didn't have any previous experience of office work, but everyone was very friendly and they taught me a lot in the time that I was there."

"The position of Assistant Manager at the Rhiwbina Tenovus Cancer Care shop where I had previously volunteered was advertised during this time so I decided to apply. I got the job and after three months, I was promoted to Shop Manager. I would encourage everyone to give volunteering a go. It's a great way to get involved in your local community, to meet new people, and to gain various kinds of work experience."

◦ **We developed innovative, accessible and cost effective ways to recruit and select volunteers and staff**

We've continued to use the most cost effective ways to attract and recruit the best people we can. We aim to recruit the best match to our roles so we have designed our recruitment processes to allow candidates to demonstrate their skills throughout the selection process, in a way that allows people to show us what they can do. This has included live auditions for our choir roles, video CVs for our Storyteller role and practical exercises that allow applicants to get a feel for what's involved.

We ran a local opportunities event in Cardiff aimed at promoting life in the third sector. Working with local businesses and external providers helped us broaden our volunteer base, build community partnerships and helped staff and volunteer engagement.

We also worked closely with local colleges, universities and local partners attending job fairs, taking part in career panels, and working together on consultancy projects. This has allowed us to promote the organisation, learn from students about ways we can improve our services, and recruit and attract new people to the Charity.

◦ **We developed a recognition/non-financial rewards scheme that recognises the contribution of people to the charity, enhances engagement and celebrates success**

We continued to work to create an environment where staff and volunteers feel valued and that their contribution matters. Volunteers contribute hundreds of thousands of hours to help us achieve our aims and objectives, and it would be impossible for us to do what we do without their support. It's really important therefore that we recognise the value they bring, show them the impact they make, and say thank you for their support. Our new Recognition Guide launched this year helps us do this consistently and equitably across the Charity, so that all our volunteers know how much their contribution means to us.

Aims for 2018/19

- Support the charity in creative ways to recruit volunteers and raise awareness of the importance of volunteering across the organisation
- Raise the profile and understanding of the importance of safeguarding staff and volunteers across the organisation

Financial Review and Results for the Year

As with previous years we received our income from a wide range of sources. Total income achieved of £9.6m (£9m 2017) with the increase of £0.59m predominately due to a highly successful Capital Appeal for Mobile Support Unit 3 and funding for Mobile Support Unit 4 from the Moondance Foundation.). Our expenditure noted at £9m (£10m 2017) moved in line with our strategy and operational plans to reduce costs across the charity. Charitable expenditure for the year amounted to £3.1m which was a reduction on the previous year of £0.7m (£3.8m 2017) due to no new PhD calls being made in the year plus cost savings across the charity. Our suite of retail shops contributed £5.4m to this income which was consistent with 2017.

At the year end, including unrealised movements in its investments, we are reporting retained reserves totalling £5.85m reflecting a net increase of £0.59m from last year. The balance going forward comprises £2.25m in restricted reserves to be spent on specific purposes specified by the donors and £3.6m in unrestricted reserves, of which the Trustees have internally budgeted use for specific purposes of £0.3m. The remainder of the unrestricted reserves in the general fund are sufficient for the charity's reserve policy (pg. 26). The purpose and level of these reserves are reviewed by the Trustees annually.

The deficit on unrestricted reserves in the year which has been controlled and tightly monitored, has reduced our cash funds available to the charity, but we managed our cash flow proactively and operated throughout the year within the agreed overdraft of £0.5m. At the year end we were operating within our agreed overdraft.

After taking into account realised and unrealised gains on investments the result for the year ended March 2018 was a gain of £0.59m (2017: £0.52m loss).

The Group reserves stood at £5.85m (2017: £5.25m) at the year ended 31 March 2018. During the financial year the Trustees have reviewed the reserves policy in-line with best practice and due to the strategic review that will be taking place during 2018 have decided to maintain as a minimum unrestricted reserves at £2.8m to ensure that we have sufficient reserves in place to both meet the risk criteria set as part of the reserves policy and to secure reserves for the furtherance of the strategic and long term objectives that will be set. We are looking to utilise reserves on ongoing charitable expenditure as well as holding a % of reserves against potential falls in investment in the short term to reach our long term objective of an overall investment return of 5%.

Risk

The charity has detailed organisational and departmental risk registers which are reviewed monthly by the Senior Management Team and quarterly by the Audit Committee and the Board. Significant new risks are brought to the attention of the Audit Committee and the Board as necessary to ensure they are being actively managed. The risk assessment process identified the following major risks:

- Potential failure to support cancer patients, their families and fund research in the way we have laid out in our vision, mission and strategy

To manage this risk we have a three year strategy. Progress against each element is reported to Trustees quarterly. As part of the strategy, objectives are set for each team and monitored monthly by Senior Management. All service delivery is evaluated and results fed back into the strategic planning process.

- Potential inability to attract, recruit and retain the right staff and volunteers for key roles within the organisation

Our recruitment and selection process has been developed to reflect our values and to optimise selection of the very best people to help us deliver our strategic aims. Each employee has a training and development plan which reflects their responsibilities and enables them to deliver their work to the highest standards. We monitor retention levels monthly and exit interviews are routine and feedback from these is discussed within the relevant team.

- Potential failure to safeguard our data in line with Data Protection

We have a Data Protection Officer in post who reviews, manages and trains staff and volunteers in line with all aspects of Data Protection, as well as ensuring that all third party agreements are compliant.

We value our donors and the people we help on a day-to-day basis and we ensure that their information is safe, by continually reviewing our security systems.

○ **Potential inability to demonstrate the impact of our work to all our stakeholders**

To demonstrate our impact, we maintain close relationships with NHS professionals, the scientific community, politicians, policy makers, advocacy groups, patients, their carers and families and the wider general public. Recent developments include recruitment of a Storyteller and Research Engagement Officer. Included in our messages to stakeholders are testimonials, often on video, research publications, presentations at conferences, and invited performances by our choirs.

○ **Potential lack of public awareness of our charity, our contribution to communities and what we do**

We promote a comprehensive schedule of activities and events delivered across all communities, via the media, our website, social media, our shop windows, television documentaries and newsletters. Our brand refresh has enabled us to define who we are and what we deliver.

○ **Potential failure to secure adequate sustainable income to enable us to deliver our mission**

A donor retention plan is in place to look after the people who give to us in time or money. We have also invested in our lottery together with a legacy campaign to achieve longer term sustainable income for the charity. We have developed new corporate partnerships, initiated new events and grown our government sourced funding.

Plans for future periods

During the latter part of this financial year and post year end we have had a change in a number of trustees as well as a new chairman appointed. With this in mind a strategic review has been scheduled for October 2018 to assess the level of risk appetite across the board, to identify new sustainable income sources to support our ongoing charitable spend, and to ensure that our research and support services continue to support people affected by cancer in the most effective way. Once this strategy has been agreed a further review of reserves against the reserves policy will be undertaken to confirm our reserving policy is appropriate for our strategic aims and covers all risk areas as required.

We remain keen to continue to support the range of services that we currently have in place as well as developing further services that we feel are appropriate to people affected by cancer.

Reference and Administrative Details

Tenovus Cancer Care is a Company Limited by Guarantee (Company Number 00943501) and a Registered Charity (Number 1054015)

Committees & Trustee Membership

	Committees and Sub Committees									
	Board	Audit, Risk & Governance	Finance & General Purposes	Fundraising & Marketing	Research & Patient Services	Recruitment & Selection	Remuneration	Scientific Advisory Sub Committee	Psychosocial Research Advisory Sub Committee	Research Advisory Group
Trustees										
Prof Malcom Mason (Chairman)	•					•	•			
Richard Sims (Resigned 27 th March 2018)	•					•	•			
Prof John Lazarus (Resigned 19 th June 2018)	•				•	•				
Wyn Mears	•		•	•		•				
Nigel Williams (Resigned 20 th March 2018)	•	•	•							
Iestyn Morris	•		•							
Melanie Goward (interim post on audit)	•	•	•		•					
Michael Borrill (Deputy Chair)	•	•	•			•	•			
Simon Evans	•			•	•					
Paula Kathrens	•			•		•				
Anne-Marie Koukourava	•			•						
Prof Geraint Williams	•				•					
Dr Ann Marie Procter	•				•					
Prof Deborah Fitzsimmons	•				•					
Hugh O'Sullivan (Appointed 26 th)	•	•	•				•			
Co Opted Members										
Dr Antonia Wigley (co-opted) (Resigned December 2017)					•					
Rob Petersen (co-opted)				•						
Andrew Morgan (co-opted)				•						
Ralph Vaughan (co-opted)				•						
Gareth Jones (co-opted) (Appointed 26 September 2017)		•								

	Board	Audit, Risk & Governance	Finance & General Purposes	Fundraising & Marketing	Research & Patient Services	Recruitment & Selection	Remuneration	Scientific Advisory Sub Committee	Psychosocial Research Advisory Sub Committee	Research Advisory Group
Sub Committee Members										
Dr Charlotte Bevan								•		
Dr Doug Winton								•		
Professor Mari Lloyd-Williams									•	
Laura Osborne										•
Jan Rymer										•
Barbara George										•
Allyson Bergin-Jones										•
David Morrey										•
Lynfa Maeer										•
Lesley Radley										•
Jayne Griffiths										•
Mary Webb										•
Ann Kellaway										•
Rachelle Barlow										•

- Chair
- Committee/Sub Committee Member

Royal Patron

HRH The Princess Royal

Patrons

Rob Brydon
 Carl Edwards
 Aled Davies
 Wynne Evans
 Catrin Finch
 Connie Fisher
 Dafydd James
 Lawrence and Jackie Llewelyn-Bowen
 Sian Lloyd
 Rupert Moon
 Nigel Owens
 Kai Owens
 Leona Vaughan
 Sam Warburton

Senior Management Team

Chief Executive -Claudia McVie
 Director of Finance – Hazel Sweeney FCA
 Commercial Director –Keith Bryant
 Director of Research & Support – Rhian Edwards
 Director of Marketing & Communications - James Powell
 Director of People & Development - Julie Rees

Company Secretary

Hazel Sweeney FCA

Principal Address and Registered Office	Gleider House Ty Glas Road Cardiff, CF14 5BD
Principal Professional Advisors External Auditors	MHA Broomfield Alexander Ty Derw Lime Tree Court Cardiff Gate Business Park Cardiff, CF23 8AB
Solicitors	Blake Morgan LLP 1-9 Central Square Cardiff, CF10 1AU
Bankers	HSBC Bank plc 56 Queen Street Cardiff, CF10 4PX
Investment Advisors	Barclays Wealth 2nd Floor, Windsor Court, 1-3 Windsor Place, Cardiff, CF10 3BX

Governance and Management

Tenovus Cancer Care was originally established as an unincorporated organisation in 1943, and is now a company limited by guarantee (No. 00943501). Tenovus Cancer Care is registered as a charity with the Charity Commission (No. 1054015). Our registered office is as shown on page 21. We are governed by a Memorandum and an Articles of Association that were adopted on 3rd December 1968 and amended on 19th March 1996, 16th March 2009 and 27th March 2018.

Our Trustees and senior executives are listed on pages 20 & 21.

Subsidiary Undertakings

Tenovus Cancer Care has three wholly owned subsidiaries, Tenovus Limited, Tenovus Trading Limited and Tenovus Health Limited. All companies share their registered office with Tenovus Cancer Care.

Tenovus Trading Limited conducts trading activities, in greetings cards and other purchased goods for sale in Tenovus Cancer Care shops and at events, with all profits being covenanted to Tenovus Cancer Care. The results and year end position of the subsidiary are shown in note 4a & 4b to the financial statements.

Tenovus Health Limited was set up to develop chargeable health initiatives and services. The charity continues to try and develop these services which may be run through the charity itself, in which case these initiatives may not be run through Tenovus Health Limited in which case the company would cease to trade from the next financial year.

The Board

The Board of Trustees is responsible for the overall governance of Tenovus Cancer Care, and members are also Directors of Tenovus Cancer Care. As set out in the Memorandum and Articles of Association, the Chair of the Trustees is nominated by the Board of Trustees and elected by them.

New Trustees are appointed following a selection process involving advertisement and nomination of potential new members. When considering new Trustees, the Board consider specialist skills required through a skills audit. New Trustees are appointed by a majority of the Board of Trustees, initially for a period of three years, but can be invited to serve for a longer term. New Trustees are provided with an induction, giving them an overview of the responsibilities and activities carried out by the charity. Training on external and organisational issues is provided throughout the year.

The Board meets at least four times a year as Directors/Trustees, and as members at an Annual General Meeting, and is responsible for setting an appropriate strategy for the charity. It also ensures that relevant performance measures are in place. The Board receives regular reports on all aspects of the charity's work.

There are six established Committees. The members of these Committees include Trustees, and are attended by management and external advisors. The Terms of Reference for these Committees are summarised below.

Finance and General Purposes Committee

The Finance and General Purposes Committee takes delegated responsibility on behalf of the Board of Trustees for overseeing all financial aspects of the charity so as to ensure long term viability, including:

- Financial and operational performance and procedures;
- Annual plans and budgets;
- Investments;
- Pensions;
- Salary review;
- Human resource issues;
- Health & safety;
- Information technology.

Audit Committee

The Audit Committee has a responsibility for monitoring and reviewing:

- Policies and processes for the identification, assessment and management of risk, including financial control;
- Charity's financial statements to assess the integrity of financial reporting;
- Scope, results and effectiveness of external and any internal audit;
- Independence of the external auditors, their range of non-audit services and fees.

Fundraising and Marketing Committee

The Fundraising and Marketing Committee has a responsibility for monitoring and reviewing:

- Policies and processes for income generation including fundraising strategy, as well as retail;
- Financial income through fundraising practice and retailing, and the robustness of planning in these areas;
- The effectiveness of current fundraising and retailing activity;
- Arrangements with external agencies in providing services to support our income generation activity;
- Communication and marketing activity.

Research and Patient Services Committee

The Research and Patient Services Committee has a responsibility for monitoring and reviewing:

- Performance of the Cancer Support Team and assessing the strategy for the development of new services;
- Decisions on research spend based upon the advice of two independent advisory committees made up of experts within their field. These are the Scientific Advisory Committee, Psychosocial Research Committee, and any other appropriate, independent, peer review based guidance sought externally;
- The progress of on-going research projects.

Recruitment and Selection Committee

The Committee will take delegated responsibility on behalf of the Board of Trustees for monitoring and reviewing:

- ⊗ The composition of the Board and Trustees' skills and experience to ensure the Board has an appropriate blend of Trustees and that the Board composition is renewed appropriately;
- ⊗ Identification, introduction and proposing new members of the Board and be responsible for their induction, support and development.

Remuneration Committee

The Remuneration Committee's overall responsibility is to develop, with due regard to economy and appropriate comparators, a remuneration policy to attract, retain and motivate those people of the highest calibre who have the skills needed to achieve the Charity's objectives year on year at Director level, including the Chief Executive.

On an annual basis the committee shall:

- ⊗ Evaluate the performance and consider terms, conditions and changes in remuneration of the Chief Executive;
- ⊗ Receive from the Chief Executive draft evaluations of the performance of Directors and recommendations about terms, conditions and changes in remuneration, which it shall consider;
- ⊗ Make recommendations to the Board on the basis of its deliberations.

Scientific Advisory Sub Committee

The Committee is responsible for impartially overseeing the research activities of the charity on behalf of the Tenovus Cancer Care Board of Trustees.

The responsibilities of the committee shall be to:

- ⊗ Authorise the funding of research projects that fulfil the aims and objectives of the charity and received rigorous peer review;
- ⊗ Make recommendations to the Tenovus Cancer Care Board of Trustees with regards to research spend based upon the deliberations of the committee and any peer review-based guidance sought externally by Tenovus Cancer Care;
- ⊗ Review the progress of ongoing research projects;
- ⊗ Monitor and contribute to the development and implementation of corporate strategy;
- ⊗ Review terms of reference annually and evaluate performance and good practice.

Psychosocial Research Advisory Sub Committee

The Committee is responsible for impartially overseeing the research activities of the charity on behalf of the Tenovus Cancer Care Board of Trustees.

The responsibilities of the committee shall be to:

- ⊗ Authorise the funding of research projects that fulfil the aims and objectives of the charity and received rigorous peer review;
- ⊗ Make recommendations to the Tenovus Cancer Care board of trustees with regards to research spend based upon the deliberations of the committee and any peer review-based guidance sought externally by Tenovus Cancer Care;
- ⊗ Review the progress of ongoing research projects;
- ⊗ Monitor and contribute to the development and implementation of corporate strategy;
- ⊗ Review terms of reference annually and evaluate performance and good practice.

Chief Executive

Authority to conduct Tenovus Cancer Care's day to day activities is delegated to the Chief Executive, who is responsible for ensuring that the Board strategy and policies are carried out. A Senior Management Team reports to the Chief Executive and meets monthly.

Risk Management

The Trustees have a risk management strategy comprising:

- ◊ Quarterly reviews of the Charity's risk register at Audit Committee meetings;
- ◊ Establishment of systems and procedures designed to mitigate those risks;
- ◊ Implementation of procedures designed to minimise any potential impact on the Charity should those risks materialise.

Employees

We have staff with a wide range of skills, knowledge, professional qualifications and experience. We aim to offer fair pay to attract and retain high calibre staff in order for us to deliver our strategic aims. Our aim is for our staff to be well rewarded and to pay a salary that is competitive with other charities of a similar size in Wales. We don't have any bonus schemes or performance related pay and, aside from our pensions, all staff receive the same level of benefits. We run two pension schemes with all staff from April 2014 auto enrolled.

Staff pay is benchmarked every year externally against other charities of our size in terms of income, number of employees and location. The Senior Management Team (SMT) pay is benchmarked by an external provider and then determined by the remuneration committee made up of Trustees.

Our salaries are arranged into responsibility levels and ideally our aim is for salaries to be close to or above the median salary. Salaries are openly stated in our job adverts. Annual pay increases are paid as a percentage increase across the board and are proposed by the SMT and approved by the Finance and General Purpose Committee.

In 2017/18 the decision was made to not award an annual cost of living pay increase to all staff given the financial climate.

In light of the National Living wage increase from April 1st 2017 we reviewed our shop salaries as they were the only ones directly affected. As a result we increased our Sales Assistant and Assistant Manager pay rates accordingly.

Financial Management Policies

Reserves

On undertaking a full review of the reserves policy during the financial year the Trustees have set a reserve policy which requires that reserves be maintained at a level which ensures Tenovus Cancer Care's continuance of its core activities. Reserves are calculated on a risk based policy taking into account internal and external risks as recommended by The Charity Commission.

Restricted funds are identified together with purpose of holding such funds.

Designated funds are reviewed to ensure that they are adequate and meet future commitments.

The calculation of the required level of reserves is an integral part of Tenovus Cancer Care's planning, budgeting and forecasting cycle. It takes into account the risks associated with each stream of income and expenditure varying from budget, the planned activity level, and future commitments.

The Trustees review the level of reserves on an annual basis, discussing levels of readily realisable reserves, Tenovus Cancer Care's main commitments and the market valuation of its investments. The main risks to both income and expenditure are highlighted and a calculation made of the possible financial consequences of adverse movements.

The Trustees use this information to ensure maintenance of an adequate level of readily realisable reserves. In March 2018 the reserve's policy was reviewed, and based on the risk analysis, a readily realisable reserves figure of £2.8m was agreed as necessary. At 31 March 2018 there was £3.2m in general free reserves and while a small surplus of £0.4m has been identified it was felt that this was prudent to keep the current reserves in place until the strategic trustee review has taken place which is scheduled for October.

Investments

The charity has given discretionary powers to its investment advisors, who are regulated by the Financial Services Authority. The Trustees, who are mindful of the need for a balanced portfolio, regularly monitor the performance of the investment portfolio and view the performance of the investments during the year as satisfactory.

Realised gains in the year amounted to £38,702 (2017: £251,142) and market value at the year-end decreased by £38,217 (2017: £330,299 increase). In keeping with its objectives, Tenovus Cancer Care's policy is not to invest in any stocks or shares associated with the tobacco industry.

Pensions

The charity contributes to a voluntary defined contribution pension scheme for the majority of permanent employees and provides benefits based on voluntary contributions made. The assets of the scheme are held by the approved pension provider Aegon and are completely independent of the charity's finances. Contributions are recognised when the related supply is provided. The Charity has no legal or constructive obligation to pay further contributions in the event that these plans do not hold sufficient assets to provide future benefits.

Statement of Trustees' Responsibilities for the Financial Statements and Corporate Governance

The trustees (who are also directors of Tenovus Cancer Care for the purposes of company law) are responsible for preparing the Trustees' Report (incorporating the directors' report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and the group and of the income and expenditure of the charitable group for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP
- Make judgments and accounting estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditors

A resolution will be proposed to appoint auditors at the forthcoming Annual General Meeting.

Signed by order of the Trustees



Hazel Sweeney – Company Secretary

Date 25th September 2018

Independent Auditors' report to the members of Tenovus Cancer Care

Opinion

We have audited the financial statements of Tenovus Cancer Care Limited (the "parent charity") and its subsidiaries (the 'group') for the year ended 31 March 2018 which comprise the consolidated and parent Statement of Financial Activities, the consolidated and parent Balance Sheet, the consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

In our opinion, the financial statements:

- give a true and fair view of the state of the group and of the parent charity's affairs as at 31 March 2018 and of the group and parent's charity's income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group and charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact.

We have nothing to report in this regard.

Independent Auditors' report to the members of Tenovus Cancer Care (continued)

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report (incorporating the directors' report) have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charity or returns adequate for our audit have not been received from branches not visited by us;
- the parent charity financial statements are not in agreement with the accounting records and returns;
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement set out on page 27 the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor's report.



Sarah Case FCA DChA
Senior Statutory Auditor
For and on behalf of MHA Broomfield Alexander
Chartered Accountants & Statutory Auditors

Date 25th September 2018

**Consolidated Statement of Financial Activities for the year ended 31 March 2018
(incorporating income and expenditure account and statement of recognised gains and losses)**

	Note	Unrestricted Funds	Restricted Funds	Total 2018	Total 2017
		£	£	£	£
INCOME & ENDOWMENTS FROM:					
Donations & Legacies	2	1,519,188	1,882,058	3,401,246	2,559,599
Charitable Activities	3	-	277,985	277,985	350,916
Other Trading Activities	4	5,802,849	-	5,802,849	5,948,859
Investments	5	131,491	-	131,491	167,318
Other		5,930	-	5,930	-
TOTAL INCOME		7,459,458	2,160,043	9,619,501	9,026,692
EXPENDITURE ON:					
Raising Funds:					
Donations & Legacies	6	1,192,447	-	1,192,447	1,345,773
Other Trading Activities	7	4,714,898	-	4,714,898	4,910,044
Cost of charitable activities:					
Grants to research organisations	8a	739,511	19,177	758,688	1,051,641
Patient Services	8b	1,058,136	619,554	1,677,690	2,110,390
Support Groups	8c	433,359	54,625	487,984	473,421
Campaigns & Policy	8d	150,833	37,641	188,474	193,230
TOTAL EXPENDITURE:		8,289,184	730,997	9,020,181	10,084,499
Net gains/(losses) on investments	14	485	-	485	581,441
NET INCOME/EXPENDITURE		(829,241)	1,429,046	599,805	(476,366)
Transfers between funds	19	(18,400)	18,400	-	-
OTHER RECOGNISED GAINS/(LOSSES)					
Losses on disposal of tangible assets	13	(3,380)	-	(3,380)	(52,887)
NET MOVEMENT IN FUNDS		(851,021)	1,447,446	596,425	(529,253)
RECONCILIATION IN FUNDS					
Fund balances brought forward at 1 April 2017	19,20	4,450,759	805,779	5,256,538	5,785,791
Fund balances carried forward at 31 March 2018	19,20	3,599,738	2,253,225	5,852,963	5,256,538

The gain for the year for Companies Act purposes comprises the net income/ (expenditure) for the year of £599,805 (2017: £476,366 loss), with an additional loss of £3,380 (2017: £52,887 loss) on disposal of fixed assets giving a net gain of £596,425 (2017: £529,253 loss). There is no tax payable on any of the activities.

The notes on pages 34-56 form part of these financial statements.

Balance Sheets as at 31 March 2018

	Note	Group 2018 £	2017 £	Charity 2018 £	2017 £
FIXED ASSETS					
Tangible assets	13	677,264	872,623	677,264	872,623
Investments	14	4,013,066	4,484,390	4,013,067	4,484,391
		<u>4,690,330</u>	<u>5,357,013</u>	<u>4,690,331</u>	<u>5,357,014</u>
CURRENT ASSETS					
Current asset investments	14	200,000	-	200,000	-
Stock	15	51,335	91,749	-	33,840
Debtors	16	1,402,942	1,356,119	1,431,861	1,406,661
Cash at bank and in hand		1,140,086	52,628	1,125,735	31,614
		<u>2,794,363</u>	<u>1,500,496</u>	<u>2,757,596</u>	<u>1,472,115</u>
CURRENT LIABILITIES					
Creditors: amounts falling due within one year	17	<u>(1,631,730)</u>	<u>(1,600,970)</u>	<u>(1,604,815)</u>	<u>(1,582,442)</u>
NET CURRENT (LIABILITIES) /ASSETS		1,162,633	(100,474)	1,152,781	(110,327)
TOTAL ASSETS LESS CURRENT LIABILITIES		5,852,963	5,256,538	5,843,112	5,246,687
NET ASSETS		<u>5,852,963</u>	<u>5,256,538</u>	<u>5,843,112</u>	<u>5,246,687</u>
FUNDS					
Unrestricted					
Parent Charity	19	3,589,887	4,440,908	3,589,887	4,440,908
Subsidiary Company	19	<u>9,851</u>	<u>9,851</u>	-	-
Total unrestricted funds		3,599,738	4,450,759	3,589,887	4,440,908
Restricted					
Parent Charity	19	2,253,225	805,779	2,253,225	805,779
		<u>5,852,963</u>	<u>5,256,538</u>	<u>5,843,112</u>	<u>5,246,687</u>

The trustees have prepared group accounts in accordance with section 398 of Companies Act 2006 and section 138 of the Charities Act 2011.

The financial statements on pages 30 to 56 were approved by the board of directors on 25th September 2018 and were signed on their behalf by

Malcolm Mason - Director



Wyn Mears - Director



The notes on pages 34-56 form part of these financial statements.

Consolidated Statement of Cash Flows for the year ended 31 March 2018

	Page	2018 £	2017 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net cash provided/(used in) operating activities	33	<u>583,607</u>	<u>(1,329,460)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:			
Interest received		626	85
Dividends from investments		130,865	167,233
Proceeds from sale of investments		2,318,460	3,506,311
Foreign exchange gains/losses		(5,595)	-
Purchase of property, plant and equipment		(53,930)	(82,842)
Purchase of investments		(2,585,665)	(1,796,878)
NET CASH PROVIDED BY INVESTING ACTIVITIES		<u>(195,239)</u>	<u>1,793,909</u>
CASH FLOWS FROM FINANCING ACTIVITIES:			
Net change in cash and short term deposits (investment assets)		544,591	(481,130)
NET CASH FLOWS PROVIDED BY/(USED IN) FINANCING ACTIVITIES		<u>544,591</u>	<u>(481,130)</u>
Change in cash and cash equivalents in the reporting period		932,959	(16,681)
Cash and cash equivalents at the beginning of the reporting period		(116,087)	(99,406)
Cash and cash equivalents at the end of the reporting period (Note 21)		<u>816,872</u>	<u>(116,087)</u>

The notes on pages 34-56 form part of these financial statements.

Consolidated Statement of Cash Flows for the year ended 31 March 2018 - continued

RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH INFLOW/ (OUTFLOW) FROM OPERATING ACTIVITIES

	2018 £	2017 £
Net income/(expenditure) for the reporting period before gains and losses on investments (as per the statement of financial activities)	599,320	(1,057,807)
Depreciation of tangible fixed assets	245,909	294,088
Investment income receivable	(131,491)	(167,318)
(Increase)/decrease in debtors	(46,823)	(272,614)
Increase/(decrease) in creditors	(123,722)	(138,826)
Decrease/(increase) in stocks	40,414	13,017
NET CASH USED IN OPERATING ACTIVITIES (PAGE 32)	583,607	(1,329,460)

The notes on pages 34-56 form part of these financial statements.

Notes to the financial statements for the year ended 31 March 2018

1. ACCOUNTING POLICIES

Tenovus Cancer Care is a private company limited by guarantee and a registered charity, incorporated in England & Wales. Their registered office is 9th Floor Gleider House, Ty Glas Road, Cardiff CF14 5BD.

The principal accounting policies, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

ACCOUNTING CONVENTION

The accounts have been prepared in accordance with the charity's Memorandum and Articles and Association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The accounts have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

GOING CONCERN

The Trustees have reviewed Tenovus Cancer Care's financial position considering the impact of future activities to ensure it is appropriate to produce the accounts on a going concern basis. There are no material uncertainties about the charity's ability to continue.

BASIS OF CONSOLIDATION

The consolidated financial statements of the Group incorporate the financial statements of Tenovus Cancer Care and its subsidiary undertakings, all of which were made up to 31 March 2018. No separate company Statement of Financial Activities (SOFA) has been prepared for the Charity as permitted by section 408 of the Companies Act 2006 and paragraph 24.37 of the SORP.

CASH FLOW STATEMENT

The Charity prepares a consolidated cash flow statement and the consolidated accounts, in which the Charity's results are included and are available to the public. It has therefore taken advantage of the exemption conferred by FRS 102 Section 1 not to prepare a cash flow statement.

INCOMING RESOURCES

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that income will be received and the amount can be measured reliably.

Donations and Legacies

Legacies – entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted and the executor has confirmed that a distribution will be made or when a distribution is received from the estate. Receipt of a legacy is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to charity or the

Notes to the financial statements for the year ended 31 March 2018 - continued

charity is aware of the granting probate and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Direct giving – cash donations and regular gifts are accounted for as received.

Events – voluntary income arising from major events, principally sponsorship, is recognised in the period in which the event takes place.

Volunteer fundraising – income from Friends of Tenovus Cancer Care and local committees is accounted for on an accruals basis.

Major donors – major gifts and income from partnerships are recognised when received.

Lottery income – is accounted for on an accruals basis.

Gift Aid - is included based on claims made and an accruals basis.

Income from charitable activities

Grants, where related to performance and specific deliverables, are accounted for as the Charity earns the right to consideration by its performance. Where income is received in advance of performance its recognition is deferred until the criteria for income recognition has been met. Where entitlement occurs before income is received the income is accrued. Non-performance related grants are recognised on receipt and any unspent funds are carried forward in restricted reserves.

Trading activities

Retail income – retail income is accounted for when the sale takes place.

Events registration – fees are recognised when the event takes place. Any fees received in advance are deferred until the event takes place. Sales of merchandise are accounted for when the transaction occurs.

Investment Income

Investment income is included when receipt is probable and the amount receivable can be measured reliably.

RESOURCES EXPENDED

Expenditure is recognised when a liability is incurred, when an obligation to transfer economic benefits and is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Contractual arrangements and performance related grants are recognised as goods or services supplied. For research grants, the Charity recognises commitments in respect of liabilities to grant recipients up to the date of the annual progress assessment. Other grant payments are recognised when a constructive obligation arises and results in the payment being unavoidable.

Expenditure in raising funds are those costs incurred in attracting voluntary income and those incurred in trading activities that raise funds and includes irrecoverable VAT.

Charitable activities include expenditure associated with educational programmes and include both the direct costs and support costs relating to those activities.

Notes to the financial statements for the year ended 31 March 2018 - continued

Support costs include general management, budgeting and accounting, payroll administration, human resources, information technology, facilities and estates, general administration and health and safety and are allocated across charitable and fundraising activities under the following categories: Financial Management, People and Development, Information Systems, Facilities and Estates. These costs have been allocated to activity cost categories on a basis consistent with the use of resources, e.g. allocating staff costs by the time spent and other costs by usage.

DONATED GOODS AND SERVICES

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market, a corresponding amount is then recognised in expenditure in the period of receipt

TAX

Tenovus Cancer Care is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes. Profit from the subsidiaries is gift aided to Tenovus Cancer Care.

EMPLOYEE BENEFITS

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received. Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

FUND ACCOUNTING

The charity has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

Restricted funds – these funds are restricted by the donor or appeal for specific purposes. Restricted funds for capital spend are expended over the life of the asset. Funds restricted by the donor for revenue spend are held in restricted reserves and funds are matched against expenditure as appropriate.

Designated funds – these are unrestricted funds that have been set aside at the discretion of the trustees for particular purposes.

Unrestricted funds – these funds comprise accumulated surpluses and deficits on general funds that are expendable at the discretion of the trustees in furtherance of the objects of the charity and that have not been designated for other purposes.

Notes to the financial statements for the year ended 31 March 2018 - continued

FIXED ASSETS

Tangible fixed assets costing more than £500 are capitalised and included at cost together with any incidental costs of acquisition.

Depreciation is calculated so as to write off the cost of tangible fixed assets on a straight-line basis over the expected useful economic lives of the assets concerned. The principle annual rates used for this purpose are:

Leasehold improvements to shops	5 yrs, 10 yrs or remaining lease term
Furniture, fittings and equipment	10%, 15% and 25%
Motor Vehicles	25% - 33.33%
Mobile Units	5-10%
Short leasehold premises	over the period of the lease

Impairment of fixed assets

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is, recognised immediately in income/ (expenditure) for the year, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately, unless the relevant asset is carried in at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

STOCKS

Stocks comprise of merchandise purchased for resale and consumables and are stated at the lower of cost and net realisable value and are less any provisions for slow moving stocks. Donated goods for sale in the Groups' charity shops are not valued.

OPERATING LEASES

Rental costs under operating leases are charged on a straight-line basis to the SOFA over the lease term.

Notes to the financial statements for the year ended 31 March 2018 - continued

INVESTMENTS

Fixed asset investments in quoted shares, traded bonds and similar investments are valued initially at cost and subsequently at fair value (their market value) at the year end. The same treatment is applied to unlisted investments unless fair value cannot be measured reliably in which case it is measured at cost less impairment.

Investments in subsidiaries are included within the financial statements at cost. A subsidiary is an entity controlled by the charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

Investments held for resale or pending their sale and cash and cash equivalents with a maturity date of less than one year are treated as current asset investments.

CURRENT ASSET INVESTMENTS

The charity has investments which it holds for resale or pending their sale and cash and cash equivalents with a maturity date less than one year. These include cash on deposit and cash equivalents with a maturity date of less than one year held for investment purposes rather than to meet short term cash commitments as they fall due.

They are valued at fair value except where they qualify as basic financial instruments.

CASH AT BANK AND IN HAND

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

FINANCIAL INSTRUMENTS

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through income and expenditure, are assessed for indicators of impairment at each reporting date. Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected.

Notes to the financial statements for the year ended 31 March 2018 – continued

If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in net income/(expenditure) for the year.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in net income/(expenditure) for the year.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the charity transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

PENSION COSTS

The Charity contributes to a voluntary defined contribution pension scheme for the majority of permanent employees and provides benefits based on contributions made. The assets of the scheme are held in trustee-administered funds completely independent of the Charity's finances. The Charity has no legal or constructive obligation to pay further contributions in the event that these plans do not hold sufficient assets to provide future benefits.

Auto-enrolment for the Charity commenced in April 2014 and the Charity is complying with its obligations.

FOREIGN EXCHANGE POLICY

Transactions in foreign currency are recorded at the rate of exchange prevailing at the time of the transaction. Foreign currency balances are translated into sterling at the exchange rates prevailing at the balance sheet date. Any resulting gains or losses on exchange are included in the SOFA.

CRITICAL ACCOUNTING AND JUDGEMENTS

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future period

Notes to the financial statements for the year ended 31 March 2018 - continued

2. DONATIONS & LEGACIES

	Unrestricted £	Restricted £	2018 £	2017 £
Donations & Gifts	829,947	1,633,939	2,463,886	981,791
Legacies	525,484	-	525,484	1,172,001
Trusts & Foundations	17,100	248,119	265,219	254,948
Donated goods and services	146,657	-	146,657	150,859
	<u>1,519,188</u>	<u>1,882,058</u>	<u>3,401,246</u>	<u>2,559,599</u>

3. CHARITABLE ACTIVITIES

	Unrestricted £	Restricted £	2018 £	2017 £
Big Lottery Grant Fund	-	-	-	50,000
Burdett Trust	-	-	-	50,000
Welsh Assembly Government	-	205,438	205,438	205,438
Money Advice Service	-	72,547	72,547	21,314
Glynneath Health & Wellbeing	-	-	-	24,164
	<u>-</u>	<u>277,985</u>	<u>277,985</u>	<u>350,916</u>

4. OTHER TRADING ACTIVITIES

	2018 £	2017 £
Shop income	5,237,529	5,104,096
Trading in subsidiaries (4a) & (4b)	177,124	341,618
Events	236,922	351,668
Lottery	151,274	151,477
	<u>5,802,849</u>	<u>5,948,859</u>

Notes to the financial statements for the year ended 31 March 2018 – continued

4a. TRADING OPERATIONS IN SUBSIDIARY

The Charity has a trading subsidiary, Tenovus Trading Limited, company number 01157332, a company limited by guarantee which is incorporated in the UK. The subsidiary sells greeting cards, calendars and other promotional goods, and covenants all its taxable profits to Tenovus Cancer Care. A summary of its trading results follows.

INCOME & EXPENDITURE ACCOUNT	2018 £	2017 £
Turnover	161,190	311,050
Net operating expenses	(125,521)	(190,720)
Operating surplus	<u>35,669</u>	<u>120,330</u>
Amount covenanted to Tenovus Cancer Care	(35,669)	(120,330)
Retained in subsidiary	<u>-</u>	<u>-</u>
A summary of its aggregate assets, liabilities and funds is as follows:		
Assets	81,284	78,795
Liabilities	(71,433)	(68,944)
Funds	<u>9,851</u>	<u>9,851</u>

4b. TRADING OPERATIONS IN SUBSIDIARY

The Charity has a trading subsidiary, Tenovus Health Limited, company number 08146954, a company limited by guarantee which is incorporated in the UK. The subsidiary, and covenants all its taxable profits to Tenovus Cancer Care. A summary of its trading results follows.

INCOME & EXPENDITURE ACCOUNT	2018 £	2017 £
Turnover	15,934	30,568
Net operating expenses	(15,934)	(30,568)
Operating surplus/deficit	<u>-</u>	<u>-</u>
Amount covenanted to Tenovus Cancer Care	-	-
Retained in subsidiary	<u>-</u>	<u>-</u>
A summary of its aggregate assets, liabilities and funds is as follows:		
Assets	1,733	17,809
Liabilities	(1,732)	(17,808)
Funds	<u>1</u>	<u>1</u>

On consolidation net operating expenses are £41,434 (2017:£ 33,335).

Notes to the financial statements for the year ended 31 March 2018 – continued

5. INVESTMENT INCOME

	Unrestricted £	Restricted £	2018 £	2017 £
Dividend income	130,865	-	130,865	167,233
Interest receivable	626	-	626	85
	<u>131,491</u>	<u>-</u>	<u>131,491</u>	<u>167,318</u>

6. EXPENDITURE FOR RAISING FUNDS

	Unrestricted £	Restricted £	2018 £	2017 £
Donations & Gifts (6a)	851,898	-	851,898	1,098,430
Donated goods and services (6b)	146,657	-	146,657	150,859
Legacies and Trusts	166,153	-	166,153	40,701
Lottery	5,874	-	5,874	24,935
Investment Management Costs	21,865	-	21,865	30,848
	<u>1,192,447</u>	<u>-</u>	<u>1,192,447</u>	<u>1,345,773</u>

6a. DONATIONS & GIFTS

	Unrestricted £	Restricted £	2018 £	2017 £
Staff & other related costs	427,461	-	427,461	635,382
Other overhead costs	184,194	-	184,194	231,353
Publicity	49,077	-	49,077	18,438
Support costs	191,166	-	191,166	213,257
	<u>851,898</u>	<u>-</u>	<u>851,898</u>	<u>1,098,430</u>

6b. DONATED GOODS AND SERVICES

	Unrestricted £	Restricted £	2018 £	2017 £
Publicity	89,757	-	89,757	92,425
Mobile Unit equipment & services	56,900	-	56,900	56,900
Goods & Services	-	-	-	1,534
	<u>146,657</u>	<u>-</u>	<u>146,657</u>	<u>150,859</u>

Notes to the financial statements for the year ended 31 March 2018 - continued

7. OTHER TRADING ACTIVITIES

	2018 £	2017 £
Event costs	198,517	193,478
Retail shops costs (7a)	4,349,426	4,492,511
Cost of sales on new goods (subsidiary) (note 4a)	125,521	190,720
Tenovus Health costs (subsidiary) (note 4b)	41,434	33,335
	<u>4,714,898</u>	<u>4,910,044</u>

	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
7a. DIRECT COSTS				
Staff & other related costs	1,147,060	-	1,147,060	2,067,646
Rent, rates & insurance	2,050,870	-	2,050,870	1,239,973
Other costs	319,870	-	319,870	392,481
Utilities	187,742	-	187,742	192,857
Consumables	52,507	-	52,507	28,863
Repairs & renewals	123,472	-	123,472	48,867
Depreciation	89,485	-	89,485	114,638
Support costs (9 totalled with subsidiaries less recharges in 2018)	378,420	-	378,420	407,186
	<u>4,349,426</u>	<u>-</u>	<u>4,349,426</u>	<u>4,492,511</u>

Notes to the financial statements for the year ended 31 March 2018 – continued

8. COST OF CHARITABLE ACTIVITIES

	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
8a. GRANTS TO INSTITUTIONAL RESEARCH ORGANISATIONS				
University of Cardiff	229,854	19,177	249,031	377,663
University of Wales Bangor	31,503	-	31,503	(5,734)
University of Swansea	59,960	-	59,960	(14,603)
Velindre Cancer Care	30,000	-	30,000	-
Cardiff & Vale UHB	-	-	-	39,260
University of Aberystwyth	(55)	-	(55)	49,949
University Hospital of Wales	-	-	-	100
Hywel Dda University Health Board	-	-	-	36,485
Cwm Taf Health Board	11,576	-	11,576	65,789
ABMU Health Board	28,000	-	28,000	-
Morriston Hospital	-	-	-	1,107
Royal College of Music	825	-	825	154,939
Princess of Wales	410	-	410	-
Direct costs (8ai)	215,712	-	215,712	229,324
Support costs (9)	131,726	-	131,726	117,362
	739,511	19,177	758,688	1,051,641
	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
8ai. DIRECT COSTS				
Staff & other related costs	87,732	-	87,732	154,313
Other research costs	30,156	-	30,156	27,144
Direct overheads	97,824	-	97,824	47,867
	215,712	-	215,712	229,324

Continued grant funding to institutional research organisations is dependent upon adequate progress being made with the project, determined by means of an annual project review. As a result of these terms and conditions, the Charity is required to recognise a liability for commitments made to fund grant recipients beyond the balance sheet date and up to the date of the annual review for each project. Where no annual review is present, the Charity recognises expenditure when a constructive obligation arises. This liability amounted to £647,516 at 31 March 2018 (2017: £792,996).

Notes to the financial statements for the year ended 31 March 2018 – continued

8b. PATIENT SERVICES

	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
Staff & other related costs	533,438	337,157	870,595	1,103,376
Depreciation	2,918	16,902	19,820	21,068
Direct overhead costs	137,162	81,227	218,389	205,147
Publicity	927	-	927	34,781
Support costs (9)	158,972	14,448	173,420	202,730
Mobile unit direct costs	189,893	169,820	359,713	513,128
Mobile unit support costs (9)	34,826	-	34,826	30,160
	<u>1,058,136</u>	<u>619,554</u>	<u>1,677,690</u>	<u>2,110,390</u>

8c. SUPPORT GROUPS

	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
Staff costs	290,912	42,596	333,508	289,551
Direct overhead costs	36,022	12,029	48,051	78,137
Publicity	1,595	-	1,595	5,872
Travel & Subsistence	25,371	-	25,371	28,645
Room hire	21,110	-	21,110	24,049
Support costs (9)	58,349	-	58,349	47,167
	<u>433,359</u>	<u>54,625</u>	<u>487,984</u>	<u>473,421</u>

8d. CAMPAIGNS & POLICY

	Unrestricted Funds £	Restricted Funds £	2018 £	2017 £
Staff costs	83,136	29,612	112,748	88,509
Direct overhead costs	21,548	8,029	29,577	30,142
Campaign costs	11,285	-	11,285	15,417
Support costs (9)	34,864	-	34,864	59,162
	<u>150,833</u>	<u>37,641</u>	<u>188,474</u>	<u>193,230</u>

9. SUPPORT COSTS

	Other overhead £	Staff costs £	Total 2018 £	Total 2017 £
Retail & Subsidiaries	109,117	295,053	404,170	407,186
Costs of Raising Funds	54,935	148,545	203,480	223,144
Patients Services	46,820	126,600	173,420	202,730
Mobile Units	9,403	25,423	34,826	30,160
Support Groups	15,753	42,596	58,349	47,167
Research	35,564	96,162	131,726	117,362
Campaigns & Policy	9,412	25,452	34,864	59,162
Total	<u>281,004</u>	<u>759,831</u>	<u>1,040,835</u>	<u>1,086,911</u>

Notes to the financial statements for the year ended 31 March 2018 – continued

10. STAFF COSTS AND TRUSTEES' REMUNERATION

	2018 £	2017 £
Wages & salaries	4,528,100	5,037,017
Redundancy & termination payments	39,590	37,904
Social security costs	351,450	398,408
Other pension costs (note 22)	146,358	169,296
	<u>5,065,498</u>	<u>5,642,625</u>

The number of higher paid employees was as follows:

	2018 Number	2017 Number
£60,001 - £70,000	2	1
£70,001 - £80,000	-	-
£80,001 - £90,000	1	1
£90,001 - £100,000	<u>1</u>	<u>1</u>

The number of higher paid employees for whom retirement benefits are accruing:

	2018 Number	2017 Number
£60,001 - £70,000	2	1
£70,001 - £80,000	-	-
£80,001 - £90,000	1	1
£90,001 - £100,000	<u>1</u>	<u>1</u>

Pension contributions for higher paid employees are as follows:

	2018 Number	2017 Number
£60,001 - £70,000	4,625	4,653
£70,001 - £80,000	-	-
£80,001 - £90,000	3,951	5,073
£90,001 - £100,000	<u>5,926</u>	<u>6,027</u>

No Trustee has received any remuneration from the Group during the year (2017: £nil). During the year no Trustees received reimbursement of travel & subsistence (2017: £Nil).

Key Management Personnel

The key management personnel of the parent charity comprise the Senior Management Team listed on page 21. The total employee benefits of the charity were £483,337 (2017: £497,598).

11. STAFF NUMBERS

	2018 Number	2017 Number
Average number of employees (full time equivalent)	<u>207</u>	<u>218</u>
Patient Services – costs allocated to statement of financial activities – patient services	27	37
Research – costs allocated to statement of financial activities – research costs	4	3
Support Groups – costs allocated to statement of financial activities – support groups	10	10
Income Generation Department – allocated to statement of financial activities –	28	29
Head Office – allocated to statement of financial activities	21	24
Campaigns & Policy– allocated to statement of financial activities	5	2
Communication & marketing – allocated to statement of financial activities	7	8
Shops – allocated to the statement of financial activities	105	105
	<u>207</u>	<u>218</u>

Notes to the financial statements for the year ended 31 March 2018 – continued

12. NET INCOME/ (EXPENDITURE) FOR THE YEAR

As permitted by Section 230 of the Companies Act 2006, the parent company's income and expenditure account has not been included in these financial statements.

The net income/ (outgoing) resources for the year are made up as follows:	2018 £	2017 £
Income generated by parent charitable company	9,442,377	8,685,074
Expenditure by parent charitable company	(8,878,716)	(9,860,445)
Share of net income/ (expenditure) resources generated by subsidiary and covenanted to this company	35,669	120,330
	<u>599,330</u>	<u>(1,055,041)</u>

Net incoming resources for the year is stated after charging:	2018 £	2017 £
Gift Aid income	405,998	416,612
Depreciation	245,909	294,088
Auditors' remuneration – audit fee	9,400	9,400
Land and buildings operating lease costs	1,120,076	1,211,419
Other operating lease costs	16,970	12,725
Profit/(loss) on disposal of tangible fixed assets	<u>(3,380)</u>	<u>(52,887)</u>

Notes to the financial statements for the year ended 31 March 2018 - continued

13. TANGIBLE FIXED ASSETS

Charity & Group

	Leasehold shop improvements	Motor vehicles	Furniture, fittings & equipment	Mobile Units	Short leasehold premises	TOTAL
	£	£	£	£	£	£
Cost						
At 1 April 2017	631,627	66,143	606,047	820,724	395,777	2,520,318
Additions	41,176	-	7,109	5,645	-	53,930
Disposals	(396,233)	(34,021)	(217,368)	(33,321)	(1,175)	(682,118)
At 31 March 2018	276,570	32,122	395,788	793,048	394,602	1,892,130
Depreciation						
At 1 April 2017	475,558	47,848	408,801	472,489	242,999	1,647,695
Charge for the year	78,085	10,262	55,857	85,681	16,024	245,909
Eliminated on disposal	(396,233)	(34,021)	(213,988)	(33,321)	(1,175)	(678,738)
At 31 March 2018	157,410	24,089	250,670	524,849	257,848	1,214,866
Net Book Value at 31 March 2018	119,160	8,032	145,118	268,199	136,754	677,264
Net Book Value at 31 March 2017	156,069	18,295	197,246	348,235	152,778	872,623

Notes to the financial statements for the year ended 31 March 2018 - continued

14. FIXED ASSET INVESTMENTS

	2018 £	2017 £
Group & Charity		
Fair value at 1 April 2017	4,484,390	5,131,254
Less: disposals at opening book value	(2,274,180)	(3,255,171)
Add: acquisitions at cost	2,585,664	1,796,878
Net unrealised investment gains/(losses)		
Unrestricted	(38,217)	330,299
Increase/(decrease) in cash balance	(544,591)	481,130
Fair value at 31 March 2018	4,213,066	4,484,390
Split by:		
Fixed Asset Investments	4,013,066	4,484,390
Current Asset Investments	200,000	-
Represented by:		
Quoted UK Investments		
Fixed Interest Stock, UK Government	45,358	-
Corporate bond and bond funds	421,122	974,822
Equities	3,317,107	2,763,039
Other Investments	397,801	170,260
Cash held as part of investment portfolio	31,678	576,269
Fair value at 31 March 2018	4,213,066	4,484,390
Cost at 31 March 2018	3,946,915	3,199,370

In the year to 31 March 2018 the charity had realised gains of £38,702 (2017: £251,142) and unrealised (losses)/gains of (£38,217) (2017: £330,299.)

At 31 March 2018, 4 (2017: 4) individual holding of investments represented more than 5% of the total carrying value of investments.

14b. INVESTMENT IN SUBSIDIARY

	Group 2018 £	2017 £	Charity 2018 £	2017 £
Investment in Subsidiary	-	-	1	1
	<u>-</u>	<u>-</u>	<u>1</u>	<u>1</u>

The company's investments at the balance sheet date in the share capital of companies include the following:

Tenovus Health Limited

Country of Incorporation	England & Wales
Class of share	Ordinary
Holding	100%
Principal Activity	Other Health Activities

Notes to the financial statements for the year ended 31 March 2018 - continued

15. STOCKS

	Group		Charity	
	2018	2017	2018	2017
	£	£	£	£
Consumables	-	33,840	-	33,840
Greeting cards & merchandise	51,335	57,909	-	-
	<u>51,335</u>	<u>91,749</u>	<u>-</u>	<u>33,840</u>

16. DEBTORS

	Group		Charity	
	2018	2017	2018	2017
	£	£	£	£
Amounts falling due within one year:				
Trade debtors	18,961	32,910	17,318	15,358
Amount due from subsidiaries	-	-	46,250	68,204
Other debtors	125,127	71,752	125,127	71,752
Prepayments	782,576	513,076	782,525	512,966
Accrued Income	476,278	738,381	460,641	738,381
	<u>1,402,942</u>	<u>1,356,119</u>	<u>1,431,861</u>	<u>1,406,661</u>

17. CREDITORS

	Group		Charity	
	2018	2017	2018	2017
	£	£	£	£
Amounts falling due within one year:				
Bank overdraft	323,214	168,715	323,214	168,715
Trade creditors	269,710	228,176	245,944	228,081
Accruals	809,761	995,677	806,612	992,528
Deferred income	97,803	71,836	97,803	56,552
Other creditors	131,242	136,566	131,242	136,566
	<u>1,631,730</u>	<u>1,600,970</u>	<u>1,604,815</u>	<u>1,582,442</u>

Security

The bank facility is secured on the Quoted UK Investments.

Notes to the financial statements for the year ended 31 March 2018 - continued

17. CREDITORS (CONTINUED)

DEFERRED INCOME	Group		Charity	
	2018 £	2017 £	2018 £	2017 £
Opening Balance	71,836	97,194	56,552	36,906
Released in the year	(208,281)	(294,948)	(192,997)	(249,944)
Deferred in the year	234,248	269,590	234,248	269,590
Closing Balance	<u>97,803</u>	<u>71,836</u>	<u>97,803</u>	<u>56,552</u>

18. FINANCIAL INSTRUMENTS

	Group		Charity	
	2018 £	2017 £	2018 £	2017 £
Financial assets measured at fair value				
Investments	<u>4,013,066</u>	<u>4,484,390</u>	<u>4,013,067</u>	<u>4,484,391</u>
	<u>4,013,066</u>	<u>4,484,390</u>	<u>4,013,067</u>	<u>4,484,391</u>
Financial assets measured at amortised cost				
Current Asset Investments	200,000	-	200,000	-
Trade debtors	18,961	32,910	17,318	15,358
Other debtor transactions	601,405	810,133	632,018	878,337
Cash	<u>1,140,086</u>	<u>52,628</u>	<u>1,125,735</u>	<u>31,614</u>
	<u>1,960,452</u>	<u>895,671</u>	<u>1,975,071</u>	<u>925,309</u>
Financial liabilities measured at amortised cost				
Bank overdraft	323,214	168,715	323,214	168,715
Trade creditors	269,710	228,176	245,944	228,081
Other creditor transactions	<u>941,004</u>	<u>1,132,243</u>	<u>937,854</u>	<u>1,129,094</u>
	<u>1,533,928</u>	<u>1,529,134</u>	<u>1,507,012</u>	<u>1,525,890</u>

Notes to the financial statements for the year ended 31 March 2018 - continued

19. FUNDS

Charity	Balance at 1 April 2017	Income	Expenditure	Investment gains/losses	Transfers between Funds	Balance at 31 March 2018
£	£	£	£	£	£	£
Unrestricted						
General Fund	3,709,457	7,423,789	(8,102,896)	(2,895)	249,494	3,276,949
Designated Funds						
Property Upgrade Fund	107,751	-	(47,150)	-	-	60,601
Development of Sustainable Income Streams Fund	137,004	-	(3,936)	-	-	133,068
Development of Charitable Activity	486,696	-	(99,533)	-	(267,894)	119,269
Total Unrestricted	4,440,908	7,423,789	(8,253,515)	(2,895)	(18,400)	3,589,887
Restricted						
Innovation Fund	7,496	-	(1,423)	-	-	6,073
PhD Fund	44,460	-	(16,749)	-	-	27,711
Big Lottery Grant Fund - Advantage Scheme	18	-	(18)	-	-	-
Big Lottery Grant Fund – Accelerating Ideas	9,673	-	(9,673)	-	-	-
St James's Place Foundation	17,369	34,000	(39,089)	-	(2,430)	9,850
Welsh Assembly Government	324	205,438	(205,438)	-	(324)	-
Burdett Trust Fund	288	-	(288)	-	-	-
Cancer Callback Service Fund	28,267	-	(46,532)	-	18,265	-
Bournemouth Hospital Fund	65,534	-	(46,413)	-	-	19,121
Specific Area Fund	5,719	-	(676)	-	-	5,043
Mobile Unit 2 - Capital Fund	276,494	-	(45,656)	-	-	230,838
Mobile Unit 2 - Running	1,200	20,000	(21,200)	-	-	-
Support Groups	-	15,675	(15,675)	-	-	-
Mobile Unit 1 –Capital Fund	13,125	3,000	(5,313)	-	2,430	13,242
Mobile Unit 1 – Running	-	155,000	(80,000)	-	-	75,000
CST Activity Fund	27,048	75,135	(102,642)	-	459	-
Velindre Fund	218,322	-	(54,075)	-	-	164,247
Equipment Fund	24,067	-	(2,651)	-	-	21,416
Mobile Unit 3 – Fund	1,375	629,309	-	-	-	630,684
Major Donor Fund	65,000	-	(15,000)	-	-	50,000
Campaign Fund	-	21,481	(21,481)	-	-	-
Research Fund	-	1,005	(1,005)	-	-	-
Mobile Unit 4 Fund	-	1,000,000	-	-	-	1,000,000
Total Restricted	805,779	2,160,043	(730,997)	-	18,400	2,253,225
Total charity	5,246,687	9,583,832	(8,984,512)	(2,895)	-	5,843,112
Total subsidiary	9,851					9,851
Total Group	5,256,538	9,619,501	(9,020,181)	(2,895)	-	5,852,963

Notes to the financial statements for the year ended 31 March 2018 - continued

19. FUNDS (continued)

The group balance sheet also includes non-charitable trading funds of £9,851 (2017: £9,851) held in the subsidiary undertaking Tenovus Trading Limited on behalf of Tenovus Cancer Care.

Designated Funds

The Property Upgrade Fund represents the amount required to cover anticipated future expenditure on property dilapidation and equipment at 31 March 2018.

The Development of Sustainable Income Streams Fund represents an amount used to develop and maintain sustainable income streams within the charity. The fund will be spent over a 3 year period from a tailored and robust programme of spend.

The Development of Charitable Activity Fund represents funds set aside for deliverance of the charity's objectives. A programme of spending will be drawn up during the next financial year and will be spent by 2020. Noted that monies were released from this fund in the year as not required post restructure of advice line.

Restricted Funds

The Innovation Fund represents funding for an innovation grant from Amser Justin Time.

The PhD Fund represents funding for PhD students from the Hodge Foundation and The Masonic Samaritan Fund.

The Big Lottery Grant Fund – Advantage Scheme is a 3 year project for establishing fifteen choirs across Wales for people affected by cancer.

The Big Lottery Grant Fund – Accelerating Ideas Scheme is a 1 year project looking into the expansion of choirs into England.

The St James's Place Foundation Fund represents funding for capital equipment for the Mobile Unit and funding for a Support Line Nurse. The balance represents the net book value of the equipment in fixed assets and unspent funds.

The Welsh Assembly Government Fund represents funding for Front Line Advice Services.

The Burdett Trust Fund represents funding to be applied on the Cancer Callback project funded by the Burdett Trust.

The Cancer Callback Service fund represents funding from the Burdett Trust and Moondance Foundation for an extension of the Cancer Callback project. The project is being match funded by Tenovus Cancer Care.

The Royal Bournemouth Hospital fund represents funding to be applied locally in the Royal Bournemouth Hospital from various different estates.

The Specific Area Fund represents funding to be applied in specific areas within Wales.

The Mobile Unit 2 Capital Fund represents funding to be applied on the capital build on the Mobile Unit 2 from Welsh Assembly Government, Rank Foundation, Walk the Walk, The David Hammond Charitable Trust and Wolfson Foundation.

The Mobile Unit 2 Running Costs fund represents funding to be applied on the Mobile Unit 2 running costs from The Simon Gibson Charitable Trust, Walk the Walk and Tata Steel.

The Support Groups fund represents funding for use on specific support groups.

The Mobile Unit 1 Capital Running Fund represents funding to be applied on Capital.

The CST Activity Fund relates to funding received for specific Cancer Support Team activity from trust foundations including James Tudor Foundation, Money Advice Service, Waterloo Foundation, Maesgwyn Wind Farm Community Benefit and Selar Community Benefit.

The Velindre Fund is to be applied at the Cancer Information Centre, Velindre from the Lynch Estate.

The Equipment Fund represents a legacy for the purchase of medical equipment.

The Mobile Unit 3 Capital Fund represents funding to be applied on the capital build and running costs on the Mobile Unit 3.

The Major Donor Fund represents funding from Major Donors which has been restrictive use as specified by the donors.

The Campaign Fund represents funding from Cardiff University Fund for Health & Wellbeing campaign.

Notes to the financial statements for the year ended 31 March 2018 - continued

19. FUNDS (continued)

The Research Fund represents funding for to be spent on research activities.

The Mobile Unit 4 fund represents funding for the build of Mobile Unit from the Moondance Foundation.

Transfers

Transfers are made to cover depreciation that is charged on assets bought with restricted funds but whereby the depreciation does not form part of the project. Transfers are also made to cover spend where Tenovus Cancer Care is match funding the project.

20. ANALYSIS OF FUND BALANCES BETWEEN THE NET ASSETS

	General Funds	Designated Funds	Restricted Funds	Total 31 March 2018
	£	£	£	£
Charity				
Fixed assets	428,140	-	249,124	677,264
Investments	3,549,031	-	464,036	4,013,067
Net current assets/ (liabilities)	(700,222)	312,938	1,540,065	1,152,781
	<u>3,276,949</u>	<u>312,938</u>	<u>2,253,225</u>	<u>5,843,112</u>
Group				
Fixed assets	428,140	-	249,124	677,264
Investments	3,549,030	-	464,036	4,013,066
Net current assets/ (liabilities)	(690,370)	312,938	1,540,065	1,162,633
	<u>3,286,800</u>	<u>312,938</u>	<u>2,253,225</u>	<u>5,852,963</u>

21. ANALYSIS OF NET FUNDS

	1 April 2017 £	Cash flows £	31 March 2018 £
Net cash analysed in the balance sheet			
Cash at bank and in hand	52,628	1,087,458	1,140,086
Overdraft	(168,715)	(154,499)	(323,214)
Net funds	<u>(116,087)</u>	<u>932,959</u>	<u>816,872</u>

Notes to the financial statements for the year ended 31 March 2018 - continued

22. PENSION COSTS

The pension cost represents contributions paid by the Charity to the Tenovus Cancer Care Group Personal Pension Plan, a defined contribution scheme. During the year membership of the Pension Plan was offered to all the Charity's employees subject to certain restrictions. The Charity's contribution amounted to £141,878 (2017: £164,921). The contribution rates ranged between 2% and 7% (2017: 2% and 7%). At the year-end there was £33,967 outstanding (2017: £30,229).

The Charity also contributes to the NHS pension scheme for one nurse. The Scheme is an unfunded, defined benefit scheme that covers NHS employers, general practices and other bodies, allowed under the direction of the Secretary of State. As a consequence, it is not possible for the Charity to identify its share of the underlying scheme assets and liabilities. Therefore, the scheme is accounted for as a defined contribution scheme and the cost of the scheme is equal to the contributions payable to the scheme for the accounting period. The total employer contribution payable in the year was £4,480 (2017: £4,375).

23. COMPANY LIMITED BY GUARANTEE

The company is limited by guarantee whereby the liability of each member is limited to £1. As at 31 March 2018 there were thirteen members.

24. RELATED PARTY TRANSACTIONS

During the year Tenovus Cancer Care acted as an agent and collected monies totalling £125,520 (2017: £270,984) on behalf of its wholly owned trading subsidiary Tenovus Trading Limited. The charity also recharged overheads to Tenovus Trading totalling £25,751 (2017: £28,714). At the year end the Tenovus Cancer Care was owed £45,417 (2017: £66,580) from Tenovus Trading Limited.

During the year Tenovus Cancer Care incurred expenditure on behalf of its wholly owned subsidiary Tenovus Health Limited totalling £15,934 (2017: £17,948). The charity also recharged overheads totalling £Nil (2017 £11,218). At the year-end Tenovus Cancer Care was owed £833 (2017: £1,624) by Tenovus Health Limited.

During the year the Charity received donations totalling £16,659 (2017: £15,841) from Trustees. These donations were received without any conditions.

25. FINANCIAL COMMITMENTS

At 31 March 2018 the Charity had annual commitments under non-cancellable operating leases as follows:

	Other		Land & Buildings	
	2018	2017	2018	2017
	£	£	£	£
Expiring within one year	16,970	16,970	1,018,779	988,619
Expiring between two and five years	37,611	54,581	2,620,482	2,511,953
Expiring in over five years	-	-	553,644	721,974
	<u>54,581</u>	<u>71,551</u>	<u>4,192,905</u>	<u>4,222,546</u>

26. CONTINGENT ASSETS

In accordance with the SORP 2015 the charity has recognised legacies when it is probable that it will be received. An agent is employed to notify the Charity of bequests and a system of monitoring ensures that the legacy is tracked until receipt.

At the year end the Charity had been notified of 45 legacies (2017: 30) which had not met all of the criteria for income recognition. These totalled approximately £1,252,118 (2017: £527,012) including 5 material legacies estimated at £600,000 (2017: £190,000:(2)).

27. CAPITAL COMMITMENTS

At 31 March 2018 the Charity had the following capital commitments:

	2018	2017
	£	£
Mobile Unit 3	147,816	456,205
Mobile Unit 4	601,259	-
	<u>749,075</u>	<u>456,205</u>

Notes to the financial statements for the year ended 31 March 2018 – continued

28. COMPARATIVE SOFA

	Note	Unrestricted Funds	Restricted Funds	Total 2017	Total 2016
		£	£	£	£
INCOME & ENDOWMENTS FROM:					
Donations & Legacies	2	2,302,715	256,884	2,559,599	2,828,298
Charitable Activities	3	-	350,916	350,916	387,810
Other Trading Activities	4	5,948,859	-	5,948,859	5,897,332
Investments	5	167,318	-	167,318	181,829
Other		-	-	-	15,555
TOTAL INCOME		8,418,892	607,800	9,026,692	9,310,824
EXPENDITURE ON:					
Raising Funds:					
Donations & Legacies	6	1,325,773	20,000	1,345,773	1,644,319
Other Trading Activities	7	4,910,044	-	4,910,044	5,047,695
Cost of charitable activities:					
Grants to research organisations	8a	1,009,535	42,106	1,051,641	1,036,731
Patient Care	8b	1,333,121	777,269	2,110,390	2,216,086
Support Groups	8c	373,790	99,631	473,421	502,174
Campaigns & Policy	8d	161,038	32,192	193,230	225,721
TOTAL EXPENDITURE:		9,113,301	971,198	10,084,499	10,672,726
Net gains/(losses) on investments	14	581,441	-	581,441	(343,480)
NET INCOME/EXPENDITURE		(112,968)	(363,398)	(476,366)	(1,705,382)
Transfers between funds	19	(139,240)	139,240	-	-
OTHER RECOGNISED GAINS/(LOSSES)					
Losses on disposal of tangible assets	13	-	(52,887)	(52,887)	(6,846)
NET MOVEMENT IN FUNDS		(252,208)	(277,045)	(529,253)	(1,712,228)
RECONCILIATION IN FUNDS					
Fund balances brought forward at 1 April 2016	19,20	4,702,967	1,082,824	5,785,791	7,498,019
Fund balances carried forward at 31 March 2017	19,20	4,450,759	805,779	5,256,538	5,785,791

The loss for the year for Companies Act purposes comprises the net income/ (expenditure) for the year of £476,366 (2016: £1,705,382), with an additional loss of £52,887 (2016: £6,846 loss) on disposal of fixed assets giving a net loss of £529,253 (2016: £1,712,228). There is no tax payable on any of the activities.